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UNDERSTANDING PSYCHODERMATOLOGICAL DISTRESS: 
CONSTRUCTING A SKIN SHAME SCALE 
Literature Review 
This section offers a reVIew of the literature concerning psychodermatological 
assessment, that is, the assessment of the interface between the skin and its 
psychological correlates, and evaluates selected psychodermatological scales. Using 
defined criteria, fifty articles were identified, including twenty-three scales, which are 
reviewed in detail. Findings demonstrated that quantitative self-report scales dominated 
assessment. When evaluated against psychometric and theoretical criteria, the scales 
were found to have limited robustness and validity. These findings are discussed in 
relation to the relationship between disease severity and skin-related distress and 
subsequent theoretical and clinical implications explored. 
Research Report 
Living with a skin condition can lead to considerable psychological distress. 
Understanding the mechanisms of skin-related distress is crucial in developing a 
psychodermatological theory and devising meaningful psychological interventions. The 
III 
present study employed Kellett's (2002) theory of "dermatological shame" to construct 
a psychodermatological assessment scale for use in dermatological outpatient 
populations, in this case, at Barnsley District General Hospital dermatology department. 
The scale was subjected to exploratory factor analysis and reduced from thirty to 
twenty-four items. Reliability and validity analyses were then carried out and the results 
discussed in relation to dermatological shame and cognitive models of disfigurement 
(Kent & Thompson, 2002; Thompson & Kent, 2001). 
Critical Appraisal 
A reflexive account is offered of the research process, through four sections: project 
conception, study implementation, learning and development, including methodological 
limitations, and process issues. This section concludes with recommendations for 
fUrtllerresearch. 
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PSYCHODERMATOLOGICAL ASSESSMENT: A LITERATURE REVIEW 
1 ABSTRACT 
Objective Approaches to psychodennatological assessment are evaluated and 
future directions discussed. 
Design selective reVIew of psychodermatological scales according to 
psychometric and theoretical criteria, using the terms "psycho dermatol+", 
"dermatol+ ?psychol * distress", " skin shame/assessment/measurement". 
Method Using defined search criteria, papers describing relevant scales were 
identified from BI0S1S, PsycINFO and Medline databases. Fifty papers were included 
and twenty-three scales reviewed. 
Results Psychodermatological assessment is dominated by quantitative self-
report questionnaires based on health-related Quality of Life (referred to as QoL). These 
scales have varying degrees of psychometric robustness and clinical utility, but crucially 
lack a theoretically coherent psychological base underlying them. Scale development 
has suggested that psychological factors playa pivotal role in skin distress, but existing 
scales may not reflect this adequately. 
2 
Conclusion Psychodermatological assessment is a-theoretical and underdeveloped. 
Findings are discussed in relation to assessing the psychological mediators of skin 
distress. 
3 
2 INTRODUCTION 
2.1 Aim 
The aim of this literature review is to provide a critical overview of existing assessment 
measures of psychological distress in dermatological conditions. 
2.2 Overview 
What is it like to live with a skin condition? Can this experience be measured with any 
degree of reliability or validity? People whose appearance is significantly "different" 
from others have been found to be at increased risk of social anxiety, stigmatisation and 
shame (Ginsberg & Link, 1989, 1993; Jowett & Ryan, 1985; Kellett, 2002; Schmid-Ott, 
Burchard, Niederauer, Lamprecht & Kunsebeck, 2003; Thompson & Kent, 2001). There 
is growing interest in examining the psychological correlates of living with skin 
conditions, with a view to understanding and conceptualising this experience, and 
offering support where indicated and desired. A substantial body of literature has 
indicated that various skin conditions are associated with lowered mood and self-
esteem, with long-term implications for quality of life (Papadopoulos, Bor, & Legg, 
4 
1999; Reilly, Lavin, Kahler, & Pariser, 2003; Tulloch & Ormerod, 2003). These effects 
appear independent of disease severity; minor skin blemishes may be related to severe 
distress in some people (Carr, Harris & James, 2001; Picardi & Abeni, 2001) while 
Finlay, Khan, Luscombe, & Salek (1990) found the psychological effects of severe 
psoriasis comparable with those of cardiac failure. Anxiety, depression (Gupta & Gupta, 
2001; Hardy & Cotterill, 1982; Hughes, 1983; Linnet & Jemec, 1989; Millard, 2000; 
Sheehan-Dare, Cotterill, & Simmons, 1990) and suicidal ideation have also been 
reported (Cotterill & Cunliffe, 1997; Gupta, Sclwrk, & Gupta, 1993; Gupta & Gupta, 
1998; Picardi, Abeni, Melchi, Puddu, & Pasquini, 2000). 
The study of the interaction between the psyche and the skin has been termed 
"psychodermato10gy" (Gieler, 2003; Koo, 1995,2000; Van Moffaert, 1982) and the 
psychosocial impact of skin disease well documented (Ginsberg, 1996; Gupta & Gupta, 
1995, 1998; Koo, 1995). This review attempts to examine existing 
psychodermatological measures with the specific aim of critically reviewing (a) whether 
they satisfy defined reliability and validity parameters and (b) whether they facilitate 
biopsychosocial assessment. Biopsychosocial assessment refers to a holistic approach 
that takes into account the biological basis of skin disease, its psychological effects, and 
5 
social factors that may impact on the individual (Kellett & Gilbert, 2001). It is, 
therefore, of clinical utility. 
2.3 Search strategy 
Papers were identified using two strategies: (1) BIOSIS, PsyclNFO and Medline 
databases were searched with the terms "psycho dermatol*", "dermatol*/psychol* 
distress", "skin shame", "assessment" and "measurement": and (2) references from 
published studies. 
Papers from 1990-2004 were selected, concentrating on those published after the last 
related overview by Halioua, Beumont, & Lunel, (2000), which focused on 
dermatological QoL measurement only. Key papers published before 1990 are included. 
Papers were included if they were published in English, described 
psychodermatological measures, or reviewed psychodermatological measures. Studies 
that did not meet these criteria were excluded as the review focused on the 
psychological assessment of dermatological distress. 
6 
2.4 Rationale for Exclusions 
As the review focused on self-reported psychodermatological measures, the following 
categories of scale were excluded: ratings of disease severity and coverage, measures 
aimed at children and families and approaches to assessing disfigurement l . 
3 THE PREVALENCE OF SKIN CONDITIONS AND ASSOCIATED 
PSYC'HOLOGICAL DISTRESS 
In order to justify the need for the biopsychosocial assessment of skin conditions, it is 
crucial to underline the extent of skin disease and its associated distress. Patients' 
concerns about their skin account for about 10% of all consultations in UK general 
practice of which 75% are dealt with in primary care (Harlow, Poyner, Finlay, & Dykes, 
I Therefore, purely physiological measures like the Psoriasis Area and Severity Index (Fredrikson & Pettersson, 1978) and 
disfigurement scales, such as the Derriford Appearance Scale (DAS-S9: Carr, el al., 2001), were excluded because they have no 
specific psychodermatological items. The DAS-S9 is not specific to skin-related distress, and health-related QoL measures, such as 
the Sickness Impact Profile (UKSIP: Bergner et al .. 1981) were excluded as they assess symptoms, rather than facilitating 
biopsychosocial assessment (McKenna, Cook, Whalley, Doward, Richards, Griffiths, et al .. 2003). Using these criteria, fifty papers 
were identified and twenty-three form the focus of this review, the others being review papers. It will begin with an examination of 
the impact of skin conditions. Dermatological assessment will then be introduced, before psychodermatological scales are evaluated. 
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2000; Hunter, Savin, & Dahl, 1989). The Lambeth study (Rea, Newhouse, & Halil, 
1975) of the prevalence of skin diseases in the general population, found that 22.5% of 
the 2180 participants had skin conditions justifying medical attention. Eczema 
represented the largest group, with a prevalence of 9%. The remaining four most 
common diagnoses were acne, scaly dermatoses such as psoriasis, prurigo (chronic 
itching), and erythematous disorders (inflammation). US prevalence studies 
demonstrated that 312 people per 1000 population had one or more condition meriting 
evaluation by a dermatologist. The prevalence of skin conditions has been shown to 
peak in young adulthood at 365 per 1000 from 18-24 years (Weinstock & ehren, 2003; 
Williams, 1998) and rise from 34 years, reflecting the increase in chronic conditions 
such as psoriasis. Thus, skin conditions can potentially have a significant psychological 
impact across the lifespan. 
These prevalence levels reflect a high rate of skin disorders, but what of the associated 
distress? Many dermatological conditions can lead to disfigurement, either directly 
through the disease process or indirectly, following treatment (Thompson & Kent, 
2001). Some individuals may go on to develop psychological problems, as a 
consequence of disfigurement or other health issues (Koo, 1995) and the relating 
stigmatising reactions of others (Ginsberg & Link, 1989, 1993; Thompson & Kent, 
8 
2001). Studies of individuals with dermatological disfigurement have highlighted high 
levels of anxiety and depression (Jowett & Ryan, 1985), worthy of clinical intervention. 
3.1 Why assess dermatological distress? 
Living with a skin condition has potential implications for physiological and 
psychological health and the impact of others' reactions makes psychodermatological 
assessment a biopsychosocial issue. Indeed, the literature showed that for some 
diseases, like melasma, the psychological impact might be greater than its physical 
effects (Balkrishnan, McMichael, Camacho, Saltzberg, Housman, et al., 2003). 
Psychological assessment is necessary to inform effective interventions. Unless 
psychological aspects of dermatoses are addressed, treatment may prove ineffective 
(Williams, 1998) because interventions might not address clients' experiences and 
needs. As researchers have begun to investigate psychological problems associated with 
skin disease, this has inevitably necessitated the development of valid and reliable 
scales in order that clients can report their experiences. The development of such scales 
will now be examined. 
9 
3.2 How has dermatological distress been assessed? 
Psoriasis was the first skin condition to be assessed psychodermatologically, and its 
impact on patients' lives is well described (Finlay, 1997). Questionnaires exploring the 
subjective experiences of people with psoriasis (Job ling, 1976; Ramsay & O'Reagan, 
1988) established that it could affect well-being outside the physiological domain. 
Dermatologists have responded by attempting to assess the adverse effects of skin 
disease on Quality of Life (QoL) using replicable self-report questionnaire-based scales 
(Finlay, 1997, 1998). 
Although the first scales were disease-specific to psoriasis, they have become 
increasingly "dermatology-specific", generalisable to all skin conditions, as researchers 
have sought to reflect the specific difficulties of dermatological populations and 
compare different dermatoses. Scales have varying degrees of psychometric robustness 
(Finlay, 1997; Halioua et al., 2000), though validation studies are typically piecemeal 
(Anderson & Rajagopalan, 1997), suggesting a dearth of psychometrically robust 
psychodermatological scales. 
10 
Assessment has become dominated by quantitative methodology. Though this is 
amenable to psychometric evaluation, the sUbjective experiences of individuals with 
skin disease remain poorly described and understood. Ginsberg & Link's (1989) 
approach to studying feelings of stigmatisation in psoriasis offered patients descriptions 
of experiences including guilt and shame, but the researchers generated these 
dimensions empirically, without recourse to theory. A subjective measure of disease 
activity by Lundberg, Johannesson, Silverdahl, Hermansson, & Lindberg, (2000) 
offered individuals the opportunity to describe their experiences but has not been 
applied clinically. 
Despite the biopsychosocial nature of skin disease, the need for psychodermatological 
assessment has not always been recognised. This limited acknowledgement of the value 
of psychological input into dermatology services has clinical implications, although 
Gledhill, Keller-Jackson, & Cheesbrough, (1995) and Finlay (1997) described the 
positive evaluation of a clinical psychology service within a dermatology department. 
Attempts to develop clinical psychology services in dermatology outpatients have met 
with mixed results (Fortune, Richards, Main, O'Sullivan, & Griffiths, 1998). Thus the 
interface between psychology and dermatology remains underdeveloped. 
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Thus far, this introduction has suggested that dermatologists have driven 
psychodermatological assessment and that it is characterised by quantitative self-report 
scales with varying degrees of psychometric robustness and biopsychosocial relevance. 
In order to examine their value further, existing psychodermatological scales will now 
be evaluated. 
4 STRUCTURE OF REVIEW 
Previous overviews by Finlay (1997, 1998) and Halioua et al., (2000) have been 
practically driven, describing QoL measures in dermatology and advising the reader on 
their clinical relevance. Others have been limited to dermatology-specific (de Tiedra, 
Mercadal, Badia, Mascaro, & Lozano, 1998) or disease-specific scales (de Korte, 
Mombers & Sprangers, 2002; McKenna & Stem, 1996) and have tended to ignore 
theoretical issues (de Tiedra et al., 1998; Halioua et al., 2000). This review will utilise 
Finlay's (1997) framework, adopted by Halioua et al. (2000), that categorised scales 
into dermatology (generic) and disease-specific scales" but will attempt to build on this 
by evaluating all psychodermatological scales including those developed since their 
reviews. Each scale will be evaluated using two key criteria: 
12 
• Psychometric Robustness: this will include an examination of the scales' 
validity, reliability, and sensitivity. 
• Theoretical robustness, including an assessment of theory-practice links. 
First, dermatology-specific scales will be evaluated, and then second, disease-specific 
scales evaluated by condition, under psoriasis, acne, eczema and miscellaneous 
categories. Common methodological and theoretical concerns and limitations will then 
be discussed and critical themes emerging from the literature highlighted. This will be 
followed by conclusions and implications for further studies. 
5 PSYCHOMETRIC ROBUSTNESS CRITERIA 
In order to evaluate each scale consistently, it is critical to define each psychometric 
criterion carefully, after Cook & Campbell (1979), DeVellis (2003), Hays, Anderson, & 
Revicki, (1993) and Anastasi (1988). Firstly, reliability refers to the consistency with 
13 
which any scale assesses a trait or attribute. It is an important measurement concept 
because it relates to the practical utility of measures, as described belo~. 
ICriterion Definition 
Temporal Stability The extent to which a person's perception is constant over time, 
it "shows the extent to which scores on a test can be generalised 
over different occasions; the higher the reliability, the less 
susceptible the scores are to the random daily changes in the 
condition of the test takers or of the testing environment" 
(Anastasi, p. 117). 
Internal Consistency The degree of homogeneity among items within a scale and their 
capacity to measure a single phenomenon. A scale is internally 
consistent when its items are highly correlated with each other, 
suggesting that all items are measuring a common construct. A 
scale may only be considered trans-culturally valid if it 
demonstrates acceptable levels of reliability and validity across 
different cultural groups (Hays et al., 1993). 
Construct Validity The degree to which a scale's underlying structure can be 
identified and the extent to which such a structure reflects the 
theoretical model on which the scale is based. 
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These criteria will now be applied to the two categories of scales. With reference to the 
reliability and validity of the reviewed scales, a quality criterion ofr = 0.80 or above 
was used to indicate good reliability. It should be noted that statistically significant 
reliability and validity does not necessarily indicate that any scale possesses clinical 
utility. For this reason, factors crucial to utility, such as face and ecological validity and 
scale length are also discussed. For the purposes of psychometric evaluation, correlation 
Criterion Validity "The effectiveness of a test in predicting an individual's 
performance in specified activities" (Anastasi, p. 145). Criterion 
validity implies an empirical association between an item or 
scale and a "gold standard" criterion, whether or not the 
theoretical basis for that association is understood. DeVellis 
(2003) argues that criterion validity is the preferable standard of 
validity because it is temporally neutral. 
Content Validity The extent to which a set of items reflects a content domain, 
involving "the systematic examination of the test content to 
determine whether it covers a representative sample of the 
behaviour domain to be measured" (Anastasi, p. 140). 
Face Validity The capacity of a scale or item to appear meaningful to the 
reader. 
Ecological Validity The validation of related performance on a scale across samples 
and settings within the same society. 
Sensitivity The ability of any scale to reflect underlying changes over time. 
15 
coefficients were defmed operationally as "high" at r = 0.80 or above, "moderate" at 
0.60-0.80 and "low" at 0.40 or below (Anastasi, 1988). 
6 DERMATOLOGY-SPECIFIC SCALES 
These measures have attempted to assess the psychological manifestations of 
dermatological conditions and associated medical interventions (Halioua et al., 2000). 
Those reviewed below have varying degrees of psychological or psychosocial content, 
addressing one or more dimensions of psychological functioning, e.g. mood, 
perceptions, behaviour or cognitive factors associated with skin distress. Each scale will 
be described briefly before being evaluated. 
6.1 The Dermatology Life Quality Index (DLQI: Finlay & Khan, 1994) 
The ten-item DLQI purports to measure dennatology patient's health-related QoL over 
the previous week from a broadly psychosocial perspective, using six subscales 
covering "symptoms and feelings", "daily activities", "leisure", "work and school", 
"personal relationships" and "treatment". 
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Over 200 references have utilised the DLQI (Finlay, 2003) and most examinations of its 
psychometric robustness are favourable (Badia, Mascaro, & Lozano, 1999; Hahn, Melfi, 
Chuang, Lewis, Gonin, et al., 2000). It has been utilized with most chronic skin disease 
populations, including psoriasis (Badia et aI., 1999; Mazzotti, Picardi, Sampogna, Sera, 
Pasquini, et al., 2003; McKenna et al., 2003; M0rk, Wahl, & Mourn, 2002; Nichol, 
Margolis, Lipan, Rowe, & Quell, 1996; Touw, Hakkart-Van Roijen, Verboom, Paul, 
Rutten, et aI., 2001), acne (Mallon, Newton, Klassen, Stewart-Brown, Ryan et al., 1991; 
Klassen, Newton, & Mallon, Newton, 2000), dermatitis (Eun & Finlay, 1990; Herd, 
Tidman, M. J., Ruta, D. A., & Hunter, 1997; Reilly et al., 2003), atopic eczema (Finlay, 
1987), vitiligo (Kent & AI-Abadie, 1996; Papadopoulos, Bor & Legg, 1999), melasma 
(Balkrishnan, McMichael, Camacho, Saltzberg, & Housman, 2003), dermatology out-
patients (Jayaprakasam, Darvay, Osbourne, & McGibbon, 2002; Hahn, Melfi, Chuang, 
Lewis, & Gonin, 2000; Hongbo, Harrison, Salek, & Finlay, 2003a), inpatients 
(Mazzotti, Picardi, Sampogna, Sera, Pasquini, 2003)~ Behyets syndrome and Darier's 
disease, suggesting strong generalisability. 
The DLQI has been shown to exhibit high test-retest reliability over 1 week: r = 0.99, 
P<O.OOOI (Finlay & Khan, 1994) and internal reliability from r = 0.23-0.70 (Finlay & 
Khan, 1994). Independent studies have evidenced its internal consistency (McKenna et 
17 
aI., 2003; Zachariae, Zachariae, Ibsen, Mortensen, & Wulf, et al., 2003) and one-week 
test-retest correlation (r = 0.93, Zacharaie et aI., 2003). 
The construct validity of the DLQI has been shown through comparisons with 200 
dermatology outpatients and 100 controls (Finlay & Khan, 1994) and a random sub-
sample of 30 patients with a sample population of 537 (Hongbo et al., 2003a), although 
factor analysis (Kent & AI-Abadie, 1996) found no evidence for the existence of the 6 
proposed dimensions, suggesting that the data were better described in 3 categories. The 
DLQI's criterion validity has been demonstrated with acne-specific scales, the Psoriasis 
Disability Index and the SF-36 (Lundberg, Johannesson, Silverdahl, Hermansson, & 
Lindberg, 2000) and it discriminates effectively between patients with different 
conditions (Finlay & Khan, 1994), inpatients and outpatients (Zachariae et al., 2003), 
those whose psoriasis improved and those who remain unchanged (Mazzotti et al., 
2003), and vitiligo patients with successful outcomes and those with treatment failure. 
The low mean DLQI score of 0.5 for non-clinical controls demonstrated by Finlay & 
Khan in their original study suggests that it discriminates well between dermatological 
populations and healthy controls. 
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The DLQI is highly sensitive to a nurnber of external criteria, including age of onset and 
global severity (Nichol, Margolis, Lipan, Rowe & Quell, 1996), (in contrast with other 
dennatology-specific scales, such as Skindex-29), to clinical improvement, especially in 
symptoms and feelings (Shikiar, Bresnahan, Stone, Thompson, & Koo, 2003) and to 
change after 4 months of pharmacological treatment in acne (Klassen et aI., 2000). 
The DLQI appears to have face validity and is considered clinically useful 
(Jayaprakasam et aI., 2002). It has been applied in North America (Hahn et aI., 2000), 
translated into Norwegian (Merk, Wahl, & Mourn, 2002) and proposed as a standard 
measure in Spain (de Tiedra et al., 1998). Swedish and Danish DLQI data are also 
available (Lundberg et a/., 2000; Zachariae et al., 2003). However, evidence of the 
DLQI's trans-cultural validity is equivocal as its mean and standard deviation scores 
have differed greatly: Mazzotti et al. (2003) found a DLQI mean of 8.7+/-6.0 in an 
Italian dennatology sample, in contrast to Jayaprakasam et al. 's London study that 
yielded a mean of 4.9 +/- 4.4, suggesting that the DLQI may be unstable. Zacharaie et 
al. 's (2003) Danish mean outpatient (7.9) and inpatient (12.9) scores were equivalent to 
the original English means of 7.3 and 13.2. Hahn et al. (2000) and Lundberg et al. 
(2000) found lower DLQI scores in U. S. and Swedish samples, though this may have 
been due to the lower disease severity. However, other studies have yielded 
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unexpectedly high and low mean DLQI scores of 18 (Finlay, 1997) and 4.82 (Kent & 
AI-Abadie, 1996), suggesting that it may be sensitive to changes in sample or skin 
condition. Furthermore, the DLQI has been applied in developed, Caucasian societies 
only. An illustrated version of the DLQI (Diba, Loo, Chawla, & Finlay, 2002; Loo, 
Diba, Chawla, & Finlay, 2003) that might be applied successfully trans-culturally and 
with people with hearing and literacy impairments has not demonstrated exact 
equivalence with the text versions, suggesting an absence of ecological validity. 
The DLQI has other drawbacks: Herd et aZ., (1997) demonstrated that while some items 
correlated moderately with the Patient Generated Index (Ruta, Allen, Herd, & Tidman, 
1998), a semi-quantitative measure of health-related QoL, DLQI totals showed inverse 
correlations with the PGI. The apparently poor life quality shown by the PGI was not 
reflected in DLQI scores, because the PGI allows patients to state which aspects they 
feel are most impaired - a more ecologically valid approach. Perhaps the greatest 
psychometric weaknesses of the DLQI are that no normative data are available 
(Lundberg et aZ., 2000) and that its sub-scales contain too few items to be considered 
reliable or valid. However, despite some limitations, the literature ,reflects the overall 
psychometric robustness of the DLQI in its widespread use as a criterion measure in 
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scale development (Clark, Allen, Herd, & Tidman, 1997; Balkrishnan et al., 2003; 
McKenna et al., 2003). 
6.2 Skindex-29 (ehren, Lasek & Quinn, 1996) 
The 29-item Skindex is a relatively new, less widely tested dermatology-specific scale 
(de Korte et al., 2002), containing five psychological dimensions. It has been found to 
be generalisable across skin conditions (Chren, Lasek, & Quinn, 1997a, 1997b), 
including acne (Lasek & Chren, 1998), melasma (Balkrishnan et al., 2003) and general 
dennatology patients (Chren et al., 1997a; ehren, Lasek, Flocke & Zyzanski, 1997b). It 
has been shown to have high test-retest reliability (0.88-0.92); internal consistency (0.87 
to 0.96) and high internal reliability (0.96) for each scale in a large sample (Chren et ai., 
1996; de Korte et al., 2002) and was more sensitive to skin-related aspects of health 
than the SF-36 (Chren et al., 1997b). The external criterion validity of Skindex-29 has 
been mixed: Balkrishnan (2003) demonstrated that Skindex-29 had less discriminative 
power between groups of women with psychological problems, than a melasma-specific 
scale derived from it, whereas Chren et al. (1996) found that patients with low, medium 
or high Skindex-29 scores differed similarly in SF-36 scores; however, some patients 
were free from social effects on the SF-36 recorded high Skindex-29 scores. 
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Its construct validity has been demonstrated by factor analysis and trials of convergent 
and divergent validity (Chren et ai., 1996; Chren et ai., 1997a, 1997b): factor analysis 
identifying 3 a priori scales. Its reduction to 29 items from 61 might have jeopardised 
content validity but Chren et ai. (1997b) found that Skindex-29 showed increased 
utility. Moreover, Chren, Lasek, Sahay & Sands (2001) recently demonstrated the 
measurement properties of Skindex-16, a briefer QoL measure, while de Korte et ai. 
(2002) found it to be the most valuable dermatology questionnaire for psoriasis 
research, based on internal structure, reliability and validity criteria. 
6.3 Dermatology QoL Scales (DQLS: Morgan, McCreedy, Simpson & Hay, 
1997) 
The 29-item DQLS measures the psychosocial impact of skin conditions by 4 scales of 
embarrassment, despair, irritableness and distress, suggesting it may be more useful to 
clinical psychologists. The DQLS has been shown to have high internal consistency 
(0.83-0.92) (Morgan et ai., 1997) and test-retest correlation of 0.84 over 7-10 days 
(Ashcroft, McCreedy, Simpson, & Hay, 1999). In terms of construct validity, it 
discriminated between dermatological populations when cross-validated against the 
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Nottingham Health Profile (NHP: Hunter, Savin, & Dahl. 1989) and demonstrated 
greater sensitivity to acne and psoriasis patients' experiences than to those of 
individuals with other conditions, although the extent of the correlation was not 
specified (de Tiedra et al., 1998). However, its responsiveness remains untested (de 
Tiedra et al., 1998) and its length may compromise clinical utility in dermatology and 
psychology settings. 
6.4 Dermatology-Specific QoL (DSQL: Anderson & Rajagopalan, 1997) 
The DSQL comprises 43 contact dermatitis-specific and 44 acne-specific items, which 
render it a semi-dermatology-specific scale. It focuses on QoL and contains 9 SF -36 
items assessing emotional welfare. Anderson & Raj ago pal an, (1997) demonstrated 
internal consistency (0.70 to 0.95), test-retest reliability (0.81 to 0.89) and external 
criterion validity (0.38 to 0.67) with patients' global distress scores, though they did not 
specify what this included. DSQL scores correlated with patients' perceived seriousness 
of their skin condition, indicating its psychological relevance and showed discriminative 
validity between patients with severe and less severe symptomology. Although de 
Tiedra et al. (1998) found it had only moderate responsiveness (0.25 to 0.29); Anderson 
& Rajagopalan demonstrated its sensitivity to clinical improvement in acne in a double 
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blind, placebo-controlled trial, albeit a lengthy assessment tool. Factor analysis 
indicated that the content of the DSQL was well characterised by the scales, although 
transposing items from the SF-36 into another context, in this case health-related to 
disease-specific QoL, may have compromised construct validity, as stand-alone items 
cannot be considered valid. 
6.5 Impact of Skin Diseases Scale (IMP ACT: Wessley & Lewis, 1989) 
The 8-item Impact of Skin Diseases Scale also assesses the psychosocial effects of skin 
disease, including embarrassment about appearance. It is available in computer format 
and this speed of application may increase its clinical utility within a busy psychology 
clinic. The literature did not offer data on the validity or reliability IMP ACT, or of its 
responsiveness to change, although de Tiedra et al. (1998) emphasised its lack of 
theory, stating that it had no psychological construct; it served simply to record 
behavioural change. Like the above scales, no independent data were available to 
support its validation. 
6.6 The Stigma Scale (Neil, 2000) 
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The Stigma Scale (Neil, 2000) was developed using psychological theory and is the 
only dermatology-specific scale underpinned by the theoretical concept of body image 
(Benrud-Larson et at., 2003), that poor body image in relation to the skin can be a result 
of experiences of enacted stigma. Factor analysis revealed 2 factors of "Stigma" with 11 
items and "Psychosocial Factors" with 9 items, although the absence of independent 
studies means that it is unclear how these concepts are differentiated. 
6.7 Questionnaire on Experience with Skin Complaints (QES: Schmid, Jager, 
Kuensebeck, Ott & Lamprecht, 1996) 
Like the scale above, the QES, based on the Questionnaire on Experience with Skin 
Complaints (Ginsburg & Link, 1989) assesses skin distress from the psychological 
perspective of stigma. Construct validity was demonstrated by factor analysis, 
identifying five factors of self-esteem, retreat, rejection, composure and concealment 
and the QESC discriminated between subgroups with different affected regions (Schmid 
et a/., 1999). 
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6.8 Adjustment to Chronic Skin Diseases Questionnaire (ACSDQ: Stangicr, 
Ehlers, & Gieler, 1998) 
The Adjustment to Chronic Skin Diseases Questionnaire was based on the 
psychological concept of self-regulation (Leventhal, 1970; Leventhal & Nerenz, 1983; 
Maes, Leventhal & de Ridder, 1996), positing that dermatological distress may be 
mediated by negative social reactions and the psychological threat of skin disease to 
body image and self-esteem, leading patients to experience reduced personal 
attractiveness (Ginsburg, 1995; Koo, 1995) and disfigurement (Jowett & Ryan, 1985). 
6.9 The Leisure Scale (Ryan, 1991) 
The Leisure scale is a behavioural measure of the impact of skin conditions on leisure 
and social time. No independent validation data are available currently. 
6.10 Coping with Chronic Skin Conditions (CSD: Niemeier, Ehlers, & Gieler, 
2002) 
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The use scale of this scale has been limited to the study of psychological factors 
associated with hand dermatoses, in which it showed discriminative validity between 
patients with high and low subjective reactions to stress. However, this narrow 
application limits its clinical generalisability. 
Thus far, this review has suggested that most dermatology-specific scales approach 
psychodermatological assessment from a broadly psychosocial perspective that includes 
psychological concepts such as embarrassment, but, though a handful are grounded in 
psychological theory, evidence of construct validity is poor. Table 1 below highlights 
variability in their psychometric robustness. It illustrates that, although many scales are 
internally and temporally reliable, independent validation of criterion validity, 
especially across cultures, is limited largely to the DLQI. Table 1 reveals a striking 
dearth of evidence for face validity and little construct validation, even for the DLQI. It 
is this lack of theoretical robustness that will be examined later in relation to 
psychological theory. Some scales have clinical utility in assessing symptoms and are 
sensitive to treatment effects, although few have evidence of generalisability. It is 
arguable that disease-specific measures, that assess one skin condition only, provide a 
more sensitive assessment of skin-related distress than generic, dermatology-specific 
scales because they respond to the particular impact of different conditions (Finlay, 
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1997). This argument will be examined below in the evaluation of disease-specific 
scales. 
6.11 Table 1: Validities, reliability and sensitivity of dermatology-specific scales 
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Criterion Internal Temporal Content Construct External Face Crols-cultural Sensitivity GeneralisabUity 
reliability reliabUity validity validity Criterion validity validity 
validity 
Scale 
DLQI (Finlay Badia el 01. Badia el 01. Hahn el Hongboel Badiaela/. Harlow de Tiedra el a/. Badia ela/. Blackford el 01. 
&I Khan, (1999) (1999) al. 01. (2003a) (1999) elal. (1998) (1999) (1995) 
1994) Finlay & Finlay & (2000) Blackford el (2000) Looel Clark ela/. Blackford el a/. 
Khan Khan Reillyel al. (1997) Reilly 01.(2003) (1997) (1996) 
(1994) (1994) a/. Clark el al. elal. Nichol el 01. KIlISsen el Finlay (1987) 
Shikiar el Hahn elal. (2003) (1997) Finlay (2003) (1996) 01. (2000) Finlay & Khan 
01. (2003) (2000) el af. (1990) Kurwa& (1994) 
Zachariae el Reilly el of. Finlay & Finlay Harris el a/. 
al. (2000) (2003) Khan (1994) (1995) (1996) 
Zachariae el Hahn elaf. Newton el lIerd el al. 
01. (2000) (2000) 01. (1997) (1997) 
Herd el 01. Reillyelal. Mallon ela/. 
(1997) (2003) (1995) 
JayaprakllSam Shikiar el Newton elaJ. 
el al. (2002» al.(2003) (1997) 
Kent & AI- Touwelal. 
Abadie (1996) (2001) 
Linnet & 
Jemec (1999) 
Loo el 01. 
(2003) 
Lundberg el 
al. (1999) 
Lundberg el 
al. (2000) 
Mallon etal. 
(1999) 
Newton el al. 
(1997) 
Newton el al. 
(1997) 
Nichol el al. 
(1996) 
Shikiar el al 
(2003) 
Reillyelaf. 
(2003) 
Ruta elaf. 
(1998) 
Zachariae '1 
af. (2000) 
DSQL Anderson & Anderson & Anderson & Anderson & Rajagopalan Anderson & 
(Auderson&l Rajagopalan Rajagopalan Rajagopalan Rajagopalan & Anderson Rajagopalan 
Rajagopalan, (1997) (1998) (1997) (1997) (1997) (1997) 
1997) Rajagopalan 
& Anderson 
(1997) 
DQOLS Morgan el Morgan et Morgan el al. 
(Morgan et al. (1997) al. (1997) (1997) 
oJ., 1997) 
Wessley & IMPACT 
(Wculey&l Lewis. (1989) 
Lewis, 1989) 
Sklndex-29 ehren etal. ehren etaf. Chren et Chren elaf. Chren et a/. 
(Cbren et oJ., (1997) (19978, af. (19978, (1997) 
1997) 1997b) (1997) 1997b) Dc Korte et 
01 .• (2002) 
Stigma Sea Ie Neil (2000) Neil 
(Neil, 2000) (2000) 
Leisure 
Questionnaire 
(Ryan, 1991) 
Stangierel Slangier" Stangier el af. ACS Slangier el Stangier et 
(§tangier et al. (1998) 01. (1998) al. (1998) (1998) al. (1998) 
oJ. 1998) 
QES(Sebmid Schmid el Schmid el af. 
et oJ., 1996) a/. (1996) (1996) 
CSD Niemeier el al. 
(Niemeier et (2002) 
aL.20021 
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7 DISEASE-SPECIFIC SCALES 
Although they are clustered around psoriasis and acne,disease-specific 
psychodermatological measures of psoriasis, acne, dermatitis, eczema and melasma 
exist. They are sensitive to the particular effects of skin conditions but their specificity 
implies low generalisability and they cannot be used to compare dermatological 
populations (Klassen et al., 2000). Joplin's (1976) questionnaire study established the 
experience of psoriasis sufferers as the most widely researched area of disease-specific 
measurement. McKenna and Stern's (1996) summary of the status of psoriasis measures 
drew attention to QoL approaches, concluding that the further development of psoriasis 
measures was necessary to assess functioning and wen·being, while de Korte et al. 's 
(2002) review of the suitability of questionnaires for psoriasis research demonstrated 
that data on psoriasis-specific scales were relatively sparse. Psoriasis scales have 
assessed psoriasis from the perspectives of disability and stress, in addition to QoL. 
These scales are evaluated by disease category below .. 
7.1 Psoriasis 
The well-established 23-item Psoriasis Disability Index (Finlay & Kelly, 1987) has been 
found through empirical study to be more representative of the impact of psoriasis on 
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patients' lives than the UK Sickness Impact Profile (UK-SIP, Bergner, Bobbitt, Carter 
& Gilson, 1981; Finlay et al., 1990; Poyner & Menday, 1998) and sensitive to the 
effects of inpatient treatment (Finlay & Kelly, 1987). Kirby, Richards, Woo, Hindle, 
Main, & Griffiths (2001) showed that inpatients had significantly higher PDI scores 
than outpatients and higher depression scores on the Hospital Anxiety and Depression 
Scale (HADS: Zigmond & Snaith, 1983), demonstrating both discriminative validity 
and external criterion validity with the HADS (Lewis & Wessley, 1990). Finlay, 
Corvest, Lefrancois, & Taieb, (2001) adjudged the PDI valid, sensitive and specific 
through its administration within a French patient support group while a Spanish sample 
has shown some evidence of trans-cultural validity. A I5-item version is also available 
to enhance clinical utility. However, Kent & AI-Abadie's (1993) findings that some PDI 
items were applicable to patients with eczema and other skin diseases challenged its 
specificity to psoriasis. It correlated moderately with disease severity scores (Finlay et 
al., 1990), though it is unclear whether or not this constitutes evidence of construct 
validity, as will be discussed later. 
Five alternative psoriasis-specific measures exist. The Salford Psoriasis Index (SPI: 
Kirby, Corvest, Lefrancois, & Taieb, 2000) has been reduced from 41 to 15 items, 
enhancing clinical utility. Its "psychosocial disability" score has been shown to 
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correlate with the PDI, indicating external criterion validity (Kirby et aI., 2001). Unlike 
the PDI, the SPI has demonstrated no correlation between disease severity and 
psychosocial functioning (Kirby et al., 2001). 
The Psoriasis Life Stress Inventory (Gupta et al., 1993) provides an index of psoriasis-
related daily stress and does not correlate with disease severity (Fortune et al., 1997a, 
1997 c), a fmding that does not necessarily negate construct validity. It has demonstrated 
specificity, showing that stress resulting from other's reactions contributed more to the 
variance in patient's disability in everyday life than any other medical or health status 
variable. Like the PDI it showed external criterion validity, lower scores on all PLSI 
subscales relating to good psychological health on th~ SF-36 mental health dimension, 
and is available in a IS-item version (Gupta & Gupta, 1995). 
The originators of the 25-item Psoriasis QoL instrument (McKenna et al., 2003) have 
demonstrated promising psychometric robustness, including temporal stability (r = 
0.89), higher specificity than the DLQI in psoriasis, and discriminative validity in terms 
of perceived disease severity. Though its sensitivity to clinical change remains untested, 
it was tested explicitly for face validity in field-test interviews and problematic items 
rejected according to systematic analysis of respondents' feedback. 
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Finlay's (1997) paper offered a limited description of the Psoriasis Stressor Scale 
(Fleischer, Feldman, & Reboussin, 1994). It has relatively little psychological content, 
focu~ing on the assessment of disease severity. To conclude psoriasis measures, 
Ginsberg and Link (1989) devised the Stigmatisation in Psoriasis Questionnaire to 
further their fieldwork into the effects of this disease. However, it does not appear in 
routine clinical usage. 
7.2 Acne 
Salek, Khan & Finlay's (1996) critique of questionnaire techniques in assessing acne 
handicap illustrated development in this area. In terms of psychometric robustness, the 
Cardiff Acne Disability Index (CADI: Motley & Finlay, 1989) and the 5-item Acne 
Disability Index showed good reliability and validity, and that the ADI (Motley & 
Finlay, 1992) was more specific to acne than the UKSIP. Salek et al. demonstrated test-
retest reliability in the ADI and CADI, in addition to internal consistency and 
discriminative validity against a control group of fifty non-patients and concurrent 
validity with the UK-SIP. An independent Australian study by Oakley (1996) confirmed 
the usefulness of the ADI: Oakley reported the same median pre-treatment ADI of 6 
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(range 2-14) as the original study, indicating cross-cultural validity. The forthcoming 
French version of the CADI might improve its cross-cultural validity (Finlay, Dreno, 
Nocera, Verriere, Myon et aZ., 2003). Finlay (1998) described the CADI as "too 
unwieldy for routine clinical use", though it could be argued that the ADI, though more 
clinically useful, may lack content validity. 
Whilst the CADI correlates with bodily acne severity, the IS-item Assessment of the 
Psychological and Social Effects of Acne (Layton, Eady & Cunliffe, 1991), which 
includes 6 items from the HADS, correlates with facial but not total acne severity (Clark 
et al., 1997; Layton, 1994). This suggests that both scales require further evidence of 
construct validity in order to ascertain exactly which effects of acne they measure. 
Furthermore, the 3 APSEA items that have shown temporal reliability and criterion 
validity within the HADS may be neither reliable nor valid within the APSEA. 
Finally, the 19-item Acne-QoL (Martin, Lookingbill, Botek, Light, Thiboutot, et al., 
2001) consists of self-perception, role-social and role-emotional domains, has high 
internal consistency, good temporal stability and was responsive to changes following 
isotretinoin treatment, although discriminative validity could not be demonstrated, due 
to the unblinded, nonrandomized nature of the treatment groups. 
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7.3 Miscellaneous Scales 
As the Eczema Disability Index is adapted from the PDI (Finlay, 1997), it may lack 
sensitivity to eczema and dermatitis patients. The Quality of Life in Atopic Dermatitis 
(Whalley, McKenna, Dewar, 2000) was developed internationally but has not been 
validated independently. The lO-item Melasma-QOL (Balkrishnan et al., 2003) assesses 
QoL impairment in melasma. Like the EDI, MELASQOL borrowed items from an 
established scale, this time Skindex-16 (Chren et al., 2001), combining them with 3 
discolouration items. MELASQOL showed discriminative validity between women 
with emotional and psychological problems and others, and external criterion validity 
with Skindex-16 and the DLQI. 
To summarise, disease-specific scales, like dermatology-specific scales, rely on 
quantitative methodology, although there is less evidence for the psychometric 
robustness of disease-specific scales than the dermatology-specific category. Acne-
related scales are especially weak in terms of temporal reliability, though arguably more 
clinically useful than dermatology-specific scales due to their generally shorter length. 
The miscellaneous group are particularly poorly validated. Like the dermatology-
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specific group, there is a dearth of construct validation and surprisingly little evidence 
of content validity, given the scales' greater specificity. Apart from the POI, their 
sensitivity is largely Untested. Validation studies of a French CADI to improve cross-
cultural validity are ongoing (Finlay et aI., 2003), although items relating to concepts 
such as disability and stress might be culturally determined and therefore not readily 
generalisable to other populations (Papadopoulos & Bor, 1999). 
7.4 Summary of psychometric robustness 
This examination has illustrated that there are fewer validation studies in the disease-
specific category than for dennatology-specific scales and less evidence of internal and 
temporal reliability. Overall, there is very little evidence of internal or face validity, and 
critically, of theoretical robustness. The DLQI and PDI are the best independently 
validated scales, though evidence is growing for the ADJ, CADI and Skindex. However, 
the limited evidence of psychometric robustness does not guarantee that 
psychodermatological scales are meaningful to individuals with skin conditions, or that 
they contribute to the understanding of skin distress. Having evaluated both categories 
of scales according to psychometric criteria, common theoretical and methodological 
concerns emerging from the literature will be discussed. 
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8 DISCUSSION 
8.1 Theoretical Concerns 
8.1.1 A-theoretical Scale Development 
Thus far, this review has demonstrated that most psychodermatological scales were 
developed as research and clinical outcome measures, rather than to contribute to the 
understanding of skin distress. The literature reviewed has confirmed that the "scant 
regard for theory" observed in most dermatological investigations by Kellett & 
Gawkroger (1999) has been reflected in psychodermatological scale development. 
Psychodermatological assessment has become dominated by quantitative self-report 
QoL questionnaires. Ashcroft et al. (1999) described QoL as "a multidimensional 
concept encompassing the physical, social and emotional well-being of a person", 
relating to their disease process and treatment. Health-related QoL measurement has 
been a useful framework around which to organise psychodermatological assessment 
but has given rise to pragmatic, rather than theoretical scale development, as QoL is a 
composite approach, rather than a unified psychological theory. Anderson & 
Rajagopalan (1998) commented that most scales did not resemble the conceptual model 
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of QoL adapted by research scientists, while McKenna et al. (2003) argued that 
dermatology and psoriasis-specific instruments such as the PDI, DLQI, PLSI, Skindex-
29 and DQLS focus on symptoms and functioning, rather than on a comprehensive 
assessment of the impact of disease. 
For this reason, most psychodermatological scales can be said to have been developed 
a-theoretically, although a limited number are more theory driven. The Stigma Scale, 
QESC and ACSDQ provide a more psychological assessment of dermatological distress 
because they were developed from the established psychological concepts of stigma and 
body image. The recently developed PSORIQUoL, MELASQOL and Acne-QoL have 
greater psychological face-validity, perhaps indicating a shift towards a greater 
emphasis on psychological theory. However, many of the scales reviewed (DLQI, 
Skindex-29, DQLS, DSQL) are limited to assessing symptoms of emotional distress. 
Instead, many psychodennatological scales favour the social dimension of 
biopsychosocial assessment, illustrating the impact of skin diseases on relationships 
(APSEA, ADI, MELASQOL, DLQI and PDI), while the PSI reflects psychosocial 
disability. Kent & Al-Abadie's (1996) factor analysis of the PDI demonstrated a two-
factor structure: one relating to the effects of psoriasis on daily living activities and the 
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other concerning public situations in which patients might be criticized. the latter of 
which could be conceptualised as social anxiety, in contrast to the a-theoretical 
"common-sense" grouping ofitems suggested by Finlay & Kelly (1987). Despite such 
evidence, it is striking that de Tiedra et al. 's (1998) selection of an instrument for cross-
cultural adaptation included no consideration of existing scales' theoretical qualities, 
indicating that this has not been valued. 
8.1.2 Item Generation 
The absence of theory has been reflected in item generation. Most scales were 
developed from qualitative reports by patients and clinicians, or "generation 
methodology" (Wackerbarth, Streams, & Smith, 2002), which has the advantage of 
conferring ecological and face validity. For example, DLQI items were based on the 
responses of 120 patients about the impact of their condition and the QES on Ginsburg 
& Link's fieldwork (1989). The DLQI combines symptoms and feelings into one scale 
though these are distinct concepts and their relationship is unclear. Items in disease-
specific scales have been similarly data driven. Finlay & Kelly (1987) devised PDI 
items by studying 54 patients with psoriasis, determining the 10 most relevant and 
independent questions according to an overall disability score (McKenna & Stem, 
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1996). Motley & Finlay (1992) selected the 5 ADI questions from qualitative studies 
(Motley & Finlay, 1989) and the PLSI was based primarily on its authors' clinical 
experience (Gupta & Gupta, 1995). The absence of conceptual grounding of items 
undermines scales' construct validity because what they purport to measure is unclear. 
For example, Kirby et al. (2000) did not clarify the origin of the SPI "Psychosocial 
Impact Score", and Finlay (1997) did not detail the origin of the APSEA' s 
"psychological" questions. The incorporation of items from other scales (DSQL, 
APSEA and MELASQOL) reflects this a-theoretical approach. 
Generation methodology has distinct advantages in affording the scales' ecological and 
content validity and clinical utility. However, it risks the omission of crucial items that 
may not be relevant to the study sample and therefore, not identified (Wackerbarth et 
aI., 2002). It also has theoretical limitations in terms of understanding skin distress 
because a-theoretical items cannot be used to explain how symptoms, emotions and 
psychological perceptions might be linked, which contributes to the scales' limited 
construct validity. Though this approach should improve face and content validity, few 
studies have demonstrated this to date. 
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8.1.3 Psychological Assessment 
Their emphasis on health-related QoL and a-theoretical approach mean that current 
scales provide only limited psychological assessment of skin distress. Psychological 
aspects of disease are considered as only one aspect of QoL assessment, which is 
reflected in the paucity of psychological scale items. Balkrishnan el al. (2003) argued 
that the DLQI and Skindex-29 assess QoL by equally weighting physical and 
psychological distress. However, as the DLQI contains only one item relating to 
emotional well-being, its ability to assess skin distress psychologically may be 
overstated. Hongbo et al. (2003a, 2003b) concluded that it had content validity in terms 
of health-related QoL, rather than psychodermatological distress. Skindex-29 was based 
on a model of disability (Chren et al., 1997a), rather than on a psychological theory of 
skin distress. Thus, it is doubtful whether even more established psychodermatological 
scales provide meaningful psychological assessment. The widespread usage of generic 
psychological scales alongside them exemplifies this (de Korte et al., 2002). 
8.1.4 Theory-Practice Links 
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This critique does not imply that existing scales are clinically worthless. Many 
individuals with skin conditions undoubtedly experience significant QoL impairment. 
However, research has suggested that it is the psychological aspects of QoL that are 
most salient to people with skin conditions. Kent & AI-Abadie (1996) found the DLQI 
to correlate more strongly with self-esteem and perceived stigma than with severity, 
underlining the salience of psychological factors. Balkrishnan et al. (2003) found that 
the QoL domains most affected included emotional well-being, which correlated with 
QoL impairment, while Salek et al. (1996) discovered that AD! psychological factors 
correlated most strongly with overall disability, and were the most salient factor 
differentiating the experiences of acne suffers and non-sufferers. An association has also 
been shown between perceived disability and self-reported losses in psychological 
functioning (Finlay et al., 1990, O'Neill & Kelly, 1996). However, despite this 
compelling evidence, existing scales do not reflect these psychological correlates. 
Not only may existing scales fail to reflect psychodermatological distress fully, their 
lack of theory means that they offer little understanding as to why some individuals 
with skin conditions experience psychological distress and others do not. Fortune, Main, 
O'Sullivan, & Griffiths, (1997a, 1997b) reported that research into the effects of 
psoriasis on patients' functioning has been concerned with the unitary assessment of 
psychological adjustment to the condition, suggesting that adjustment is one mediator of 
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the distress associated with skin disease. Biopsychosocial models of skin distress 
(Gupta & Gupta, 1995; Fleischer el al., 1994, Fleischer, Feldman, Rapp, Reboussin, & 
Eun, 1996; Kellett & Gilbert, 2001) have suggested that individuals who experience 
stress from coping with the effects of skin disease are more at risk in terms of their 
mental health. However, current scales provide no evidence about the mediators of skin 
distress or the specific direction of effects. The scales reviewed do not, therefore, offer 
the thorough psychodermatological assessment indicated by research into skin distress. 
They also have methodological weaknesses that affect their psychological value, as will 
be discussed next. 
8.2 Methodological Weakn"esses 
This section addresses methodological themes emerging from the literature regarding 
psychodermatological assessment. These include design, measurement issues, mUltiple 
testing and common method variance. 
8.2.1 Design 
Psychodermatological assessment relies on quantitative assumptions, using subjective 
assessment in questionnaire format. This approach has advantages; people with skin 
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disease can collaborate in assessment and rate the impact of their condition according to 
their perceptions. This is useful in psychological terms as self-perceptions playa crucial 
role in the development of skin distress (Gupta & Gupta, 1995, 1998; Kellett & 
Gawkroger, 1999; Koo, 1995, 2000; Martin et al., 2001) as do the meanings individuals 
attach to skin conditions (Papadopoulos et al., 1999). Self-report methodology seems to 
provide more accurate assessment as dermatologists tend to under-rate 
psychodermatological distress: studies have consistently shown low levels of 
association between subjective (i.e. patient) and objective (i.e. dermatologist) 
assessment (Jayaprakasam et aI., 2002; McKenna et al., 2003), though this may also 
indicate the inflation on symptoms on the part of the patient. 
However, though there is no evidence that the self-report approach of these scales has 
adversely affected their reliability, psychodermatological instruments have been 
criticised for being over-reliant on subjective parameters (Sugarman, McCalmont, 
Frieden, Dover, & Arndt, 2003). The studies that have found patients' severity scores to 
be consistently higher than those of the dermatologist (Kellett & Gawkroger, 1999; 
McKenna & Stem, 1996) may reflect scales' validity. The subsequent shift towards the 
objective measurement of skin conditions may be valid in methodological terms but 
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sUbjective distress may be more salient to the biopsychosocial understanding of skin 
conditions and the development of interventions. 
Despite the contribution of qualitative studies to the understanding of 
psychodermatological distress (Ginsburg & Link, 1989; Ryan, 199]). no validated 
qualitative assessment of dermatological distress has been developed, for example. in 
the form of a structured clinical interview. This may be because psychodermatological 
scale development has been driven by dermatologists, whose objective was clinical 
utility and generalisability, but means that patients' subjective experiences were less 
salient. 
8.2.2 Measurement 
Other methodological weaknesses concern measurement. Most scales rely on point 
prevalence data; some over the last week (DLQI) and others the last month (APSEA), 
so they cannot always be compared directly. They also utilize retrospective reports, 
which may limit accuracy and conflate dispositional and situational responses. There is 
. . 
evidence that distress arising from skin disfigurement changes over time (Kent, 2000; 
Thompson, 1998) according to the individual's mood, life events and environment, and 
skin flare-ups can change self-percep(ions dramatically. Thus, scales do not reflect the 
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changing nature of distress, sometimes giving a misleading picture of individuals' well-
being. Like symptom scales, they can provide an idea of the extent or degree of skin 
disease, offering the assessor a snapshot of the patient's experience. As the concept of 
QoL is multidimensional (de Tiedra et al., 1998), these scales provide information about 
symptoms, functioning, disability and psychosocial factors, critical to biopsychosocial 
assessment. However, this breadth of coverage compromises the scales' psychological 
specificity. 
Additionally, some scales were developed without adequate comparison groups, for 
example the DQLS and DSQL, resulting in no normative data being available. Others, 
like the Stigma Scale used student samples, which significantly undermines its validity 
within clinical populations. De Tiedra et al. (1998) commented that, without needing to 
achieve the highest standard, psychodermatological scales should have shown an 
acceptable level of development. While this criterion has been met by some of the 
scales reviewed, for example the DLQI, Skindex-29 and PDI, it is perhaps symptomatic 
of underdevelopment in this area that the highest standards have neither been demanded 
nor met. 
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8.2.3 Multiple Testing 
The DLQI demonstrates greater reliability, validity and sensitivity than other 
dermatology-specific scales because it is the only one to have undergone continuous 
testing, much of which is independent of the originators. Many instruments, like the 
IMPACT and APSEA have been sparsely tested (Anderson & Rajagopalan, 1998). 
8.2.4 Common Method Variance 
As the DLQI is well validated, many scales are validated against it (Clark el al., 1997; 
Herd et al., 1997; McKenna et al., 2003; Reilly et al., 2003). Skindex-29 has also been 
used as a criterion scale (Balkrishnan et al., 2003), while psoriasis and acne-specific 
scales have often been used together within the same study (Clark et al., 1997; Fortune 
et al., 1997a, 1997b; Kirby et al., 2000, 2001; Salek et al., 1996). As the ADI was 
abbreviated from the CADI, both scales were highly correlated, while the MELASQOL 
lias a similar relationship with Skindex-29. However, rather than providing evidence of 
external criterion validity, this method means that data may be flawed by statistical 
artefacts, such as common method variance. The proposed validity of many scales may 
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simply reflect either the measurement of the same underlying mechanism or over-
reliance on a single source of data. 
9 CRITICAL THEMES 
In addition to methodological and theoretical issues, the literature revealed a number of 
consistent themes concerning skin distress and its relationship with disease severity that 
will be expanded on below. 
9.1 Desynchrony 
Papers on psychodermatological scale development suggest de synchrony - a weak, non-
existent, or negative correlation between skin disease severity, especially when reported 
by dermatologists, and distress. This makes the evaluation of scales' construct validity 
an issue, due to debate regarding whether or not correlation between a scale and severity 
is evidence of validity (Jayaprakasam et al. , 2002; Jemec & Wulf, 1996; Koo, 1995). 
Desynchrony will be examined below in relation to disease severity, disability and 
clinician report. 
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9.1.1 Desynchrony between disease severity and skin distress 
Herd et al. (1997) claimed that disease severity was "the ideal measure for testing 
scales' construct validity" but it is uncertain whether or not it is predictive of 
psychological distress (Clark el aI., 1997; Finlay, 1997). Some DLQI studies have 
shown correlations of up to 0.79 with the patient-reported Psoriasis Symptom 
Assessment Scale in outpatients (Jayaprakasam el al., 2002; Lundberg el al., 1999). 
while CADI (Salek et al., 1996) and Acne-QoL (Martin et al., 2001) scores also 
revealed a trend of worsening scores with increasing severity 
However, the majority of evidence suggested weaker correlations. Changes in DLQI 
scores were only moderately correlated with changes in self-reported psoriasis severity 
(Mazzotti et al., 2003; Touw et al., 2001), while the correlation ofr = 0.51 between 
severity scores and psychological disability on the PDI and SPI suggested that for some 
patients, there was only moderate correlation (Kirby et al., 2001). Other studies found 
no relationship between Skindex-29 and severity (Chren et al., 1997a, 1997b). DLQI 
score~ and the extent of vitiligo (Papadopoulos et al., 1999), DLQI and acne severity 
(Mallon et ai., 1999) and MELASQOL and severity (Balkrishnan el al., 2003). It seems 
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therefore, that either there is only a slight relationship between severity and distress, or 
current scales are insensitive to the impact of severity on psychological well-being. 
Though QoL scales are one method of determining psoriasis severity, the evidence of 
subjective distress means that a psychological assessment tool might be equally valid. 
Balkrishnan et al. 's starting point when developing the MELASQOL was that melasma 
had a distinctly greater impact on psychosocial rather than physical aspects of a 
patient's life; an indication perhaps of a shift towards a greater recognition of 
psychological factors. 
9.1.2 Desynchrony between self and clinician report 
The provenance of assessment is, however, salient. Studies consistently show little 
association between objective and subjective disease measurement (McKenna et al., 
2003) and patients' scores correlate better with changes in treatment status (Balkrishnan 
et al., 2003). Shikiar et al. 's (2003) study suggested that patient and dermatologist-
reported assessment were significantly closer at the end of the study than at baseline, 
from r = 0.19 to 0.53, although it is unclear how this occurred. This convergence of 
clinicians' scores with self-report data suggests that existing scales' reliance on self-
report methodology may enhance their construct validity. A number of explanations 
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have been posited for this lack of relationship between disease severity and subjective 
distress3. 
10 CONCLUSION 
In summary, this review has demonstrated the significant relationship of skin disease 
with distress and the subsequent need for biopsychosocial assessment. It has identified 
that this has been addressed by the development of dermatology and disease-specific 
self-report questionnaires. However, it has also shown that though most existing 
psychodermatological scales have limited clinical utility, they are restricted to assessing 
QoL impairment or disability and offer limited psychological assessment. Whilst it is 
likely that health-related QoL impairment exists for individuals with skin disease, this 
J Severity may not predict distress because adapting to minor blemishes may be less problematic than major disfigurement, as the 
affected individual becomes habituated to revealing their skin. Dermatologists have suggested that others may react more 
sympathetically to severe disease; thereby moderating any distress the individual may feel (G. Sobey, personal communication, 16111 
December, 2003). It is likely that desynchrony arises because severity ratings and pschodcrmatolollical scales measure different 
concepts: the former measuring the objective extent of disease, and the latter the subjective experience of illness. Fortune, Richards, 
Griffiths & Main (2002) proposed that studies in a ranlle of conditions have suggested that the clinical severity of a patient's 
condition is a poor indicator of subsequent downturns in QoL or psycholollical well-beinll. The notion of a linear relationship 
between disease severity or illness and psychological variables is unlikely to be COtTCCt as it implies passivity on the patient '5 part 
and denies the conceptual difference between disease (objective pathology), and Illness (the subjective experience of changes in 
well-being). 
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approach lacks a theoretically coherent psychological basis, reflected in the diversity of 
interpretations of QoL. This inevitably leads to variability in the way that skin distress is 
measured and means that scales have not been utilized to develop the biopsychosocial 
model of skin distress. 
The literature did not reveal psychologically grounded, theoretically robust measures of 
dermatological distress. Psychometric evaluation showed that most scales, especially 
dermatology-specific instruments, have limited reliability and validity, while theoretical 
examination suggested that they have some applicability to the psychosocial assessment 
of skin diseases. However, though psychological distress is related to, and one 
component of QoL impairment, it remains a distinct domain. As psychological factors 
tend to feature as only one component of psychodermatological scales, rather than 
providing theoretical focus, the underpinnings of psychological items are critically 
unclear and subscales have no validity. Key aspects of maladjustment to skin disease, 
such as perceptions of stigma and shame reactions, are uniquely psychological, with the 
QoL concept being a poor conceptual umbrella for individuals' subjective experiences 
of skin distress. Subsequently, the criterion variables of many scales may not assess 
adequately the experiences and behaviours reported by individuals with skin conditions, 
such as avoidance and concealment. This means that individuals' experiences are not 
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being accurately portrayed and understood. In short, the scales reviewed have not 
identified the biopsychosocial processes that mediate skin distress and are of limited 
clinical use to psychologists. 
The other conclusion that can be drawn is that further psychodermatological scale 
development is required. Future scales should improve on those reviewed here by 
employing sound theoretical development and independent validation, to further inform 
the biopsychosocial model of psychodermatological distress. They should be developed 
with a dermatological population to maximize validity. A clinician-reported measure of 
psychological distress in skin conditions, or a scale designed for significant others might 
provide external triangulation. In short, psychodermatological assessment appears on 
the whole a field that is in its theoretical and methodological infancy but one that shows 
worrying abandon in terms of crucial concepts. 
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UNDERSTANDING PSYCHODERMATOLOGICAL DISTRESS: 
CONSTRUCTING A SKIN SHAME SCALE 
1 ABSTRACT 
Objective Shame has been posited as a key emotion in adjustment to disfiguring 
conditions (Kellett, 2002; Kent & Thompson, 2001). This study aimed to construct a 
psychodermatological assessment scale measuring shame, called the Skin Shame Scale 
(SSS). Exploratory factor analysis was used to refine the scale and preliminary testing 
of its reliability and validity was undertaken. 
Design A cross-sectional study using factor analysis to construct a questionnaire, 
and inferential statistics to test hypotheses. 
Method Participants (n = 162) referred to a dermatology outpatients' department 
completed the initial30-item SSS, Hospital Anxiety and Depression Scale (HADS: 
Zigmond & Snaith, 1983), Internalized Shame Scale (ISS: Cook, 1994) and perceptual 
indices of disease severity. 
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Results Principal axis analysis reduced the SSS to 24 items, comprising of 4 
factors. It was found to have satisfactory reliability, consistency and external validity, 
correlating highly with the HADS and ISS. 
Conclusion This study contributes to the psychodermatologicalliterature in 
developing a scale based on psychological theory with promising psychometric 
robustness. These findings have implications for the psychological understanding of 
skin distress. Methodological limitations are identified. 
Key words psychodermatology, shame, disfigurement, exploratory factor analysis 
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2 INTRODUCTION 
2.1 Aim 
The central aim of this study was to develop a measure of psychological distress in skin 
conditions, based on the theory of dermatological shame. 
2.2 Overview - the biopsychosocial model of skin-related distress 
The development of the scale reflected a biopsychosocial understanding of the impact of 
an individual's thoughts, emotions, motives and behaviour on their skin condition, and 
vice-versa (Root, Kent & AI'Abadie, 1994; Barankin & DeKoven, 2002; Fortune, 
Richards, Griffiths & Main, 2002a; Papadopoulos, Bor & Legg, 1999b). The 
biopsychosocial model of disease takes into account psychological and social, as well as 
physiological factors on the development and maintenance of skin diseases (Arruda & 
Moraes, 2001; Fortune, Main, O'Sullivan, & Griffiths, 1997; Fortune el al., 2002a; 
Papadopoulos, Bor & Legg, 1999). 
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This model may help to explain why some people with skin conditions become 
distressed, whilst others do not. Some may ruminate on their condition, becoming 
depressed and anxious (Barankin & De Koven, 2002; Fortune & Main, 2002a; Gupta & 
Gupta, 2001b; Papadopoulos et al., 1999; Richards, Fortune, Griffiths & Main, 2001), 
and struggling to live alongside their condition (Thompson, Kent & Smith. 2002). 
Linnet & Jemec (1999) and Lundberg, Johannesson, Silverdahl, Hermansson, & 
Lindberg, (2000) found that people with dermatitis had significantly lower life quality 
and higher state and trait anxiety than controls, even when allowing for individual 
differences, findings replicated by Rapp, Cottrell & Leary, (2001) in a sample of 
psoriasis patients. Skin conditions can generate dissatisfaction with body appearance 
(Gupta & Gupta, 2001a), shame and skin-related embarrassment (Kellett, 1996; 
Koblenzer, 1997), especially for patients with acne (Kellett & Gawkroger, 1999; 
Picardi, Abeni, Renzi, Braga, Melchi, et al., 2003), which can lead to high psychiatric 
morbidity (Picardi, Abeni, Melchi, Puddu, & Pasquini, 2000), suicidal ideation (Gupta, 
Schcprk, & Gupta, 1993; Picardi et al., 2000), attempted and completed suicide (Cotterill 
& Cunliffe, 1997; Humphreys & Humphreys, 1998); Psychosocial factors have been 
recognized as important in 24-33% of dermatology patients (Gupta & Gupta, 2001b; 
Picardi et al., 2000), while psychiatric morbidity has been estimated at between 8% 
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(Picardi et al., 2003) and 24% (Hughes, Barraclough, Hamblin, & White, 1983; Picardi 
et al., 2000,2003; Woodruff, Djang, McLendon, Heinz, & Voorhees, 1997). 
It seems, therefore, that living with a skin condition can cause significant psychological 
disturbance for some people. Papadopoulos, Bor & Legg (1 999b ) described the unique 
nature of the issues raised for people suffering from cutaneous illness, including 
adjusting to and accepting changing appearance, and arduous treatment regimes 
(Koblenzer, 1997). Such factors appear to be more influential than disease severity in 
the development of psychological distress. 
2.3 The relationship between disease severity and distress 
Most psychodermatological studies concur that the amount of distress an individual 
suffers as a result of their skin disease depends less on its clinical severity, and more on 
the person's psychological interpretation of and adaptation to the disease itself. 
Numerous studies measuring dermatological quality of life have found discrepancies 
between disease severity and psychological functioning (Clark, Goulden, Finlay, & 
Cunliffe, 1997; Finlay et al., 1990; Fortune et al., 1997; Kellett & Gawkroger, 1999; 
Kirby et ai, 2000), although evidence to the contrary exists (Chren et al., 1997). 
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Assessment of the psychometric properties of the Psoriasis Life Stress Inventory 
(Fortune, Lasek, Flocke & Zyzanski, 1997) confirmed that disease severity neither 
predicted nor correlated with stress, but that psoriasis patients could distinguish and 
process their symptoms and psychological reaction to them independently. Using the 
same scale, Kirby et al., (2000) found no relationship between severity and 
psychosocial impact, whilst Carr, Harris & James (2000) implied that distress is 
determined by neither disease site nor extent, arguing that even apparently minor skin 
blemishes can generate significant distress for many people. Linnet & Jemec (1999) 
argued that emotional and mental health-related consequences of skin conditions should 
not be inferred from disease severity, but from their psychological impact and that the 
severity of a person's skin condition is a poor indicator of their psychological outcome. 
Though there evidence exists that patients with widespread inflammatory disease are 
severely handicapped (Finlay, 2000), it seems that the psychological meaning or 
interpretation people make of disfiguring skin conditions affects their psychological 
reactions (Finlay & Dowling, 2000). Quality of life scores tend to correlate with patient, 
rather than physician-reported severity (Thomson, Wilkinson, Sommer, & Pollock, 
2002), suggesting that patients' perceptions of their disease may be salient predictors of 
distress (Martin et al., 2001; Motley & Finlay, 1992) and have been found to impact on 
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psychological adjustment and functional ability (Fortune et al., 1997). The importance 
of perceptions in the experience of skin distress (Papadopoulos, Walker, Bor & Legg, 
2001; Richards et al., 2001) results in patients and dermatologists consistently rating the 
severity and impact of skin conditions differently (Sampogna, Picardi, Melchi, Pasquini, 
& Abeni, 2003). 
Psychodermatological evidence has suggested that a number of demographic variables 
may also contribute to variance in sufferers' reactions: the impact of skin conditions 
may decrease and individuals' adjustment improve with age, a number of studies have 
found that skin diseases have a greater adverse effect on younger people (Fortune et al., 
1997; Ginsberg, 1995; Gupta & Gupta, 1995; Lundberg et al., 2000; McKenna & Stem, 
1997; Niemeier, Nippesen, Kupfer, Schill, & Gieler, 2002; Schmid, 1996; Zachariae, 
Zachariae, Ibsen, Mortensen, & Wulf, 2000). Whilst some evidence exists that older 
adults are increasingly being affected by acne (Lasek & ehren, 1998) or experience 
similar shame experiences (Harlow, Poyner, Finlay & Dykes, 2000) the weight of 
evidence suggests that older people adjust better to skin disease. Other studies have 
emphasised the greater impact of skin diseases on women than men in terms of 
symptoms and affective components (Kellett & Gawkroger, 1999; Gupta & Gupta, 
2001b; Lundberg et al., 2000; Picardi et al., 2000; Richards et al., 2001; Siegert & 
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Ward, 2002; Zachariae et al., 2000). This may be explained in part by the greater 
dependency of women on social appearance and relationships, and has been attributed 
to greater social competition among women and objectification (Herberger, 2000; 
Resnick, 2000). Evidence for the impact of visibility is persuasive (Cotterill & Cunliffe, 
1997; Papadopoulos, Walker, Aitken, & Bor, 2000). 
Thus, factors such as age, gender and location have been shown to be moderately 
predictive of skin distress. However, there is growing evidence that personality factors 
may be more salient, and that the greatest of these may be shame (Kellett, 2002). 
2.4 Stigma, body shame and dermatological shame 
If disease severity has been shown to be unrelated to skin distress, the effects of 
stigmatization, and resulting shame, are better evidenced (Ginsberg & Link, 1989, 1993; 
Koblenzer, 1997; Lim & Tan, 1991; Rapp et al., 2001; Richards et al., 2001; Vardy, 
Besser, Amir, Gesthalter, Biton, et al., 2002). Stigma has particular meaning and 
pertinence for patients with skin diseases (Kent, 2000), as its source is often visible and 
can lead to a high degree of social avoidance (Richards et al., 2001; Wessley & Lewis, 
1989). 
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The explanation for this may lie in perceptions, in this case, the interpretation and 
reactions of others, as well as how people perceive themselves. Papadopoulos et al. 
(1999b, 2001) suggested that body satisfaction is derived from a person's beliefs about 
how they are perceived by others. People develop internal cognitive representations of 
their condition and the nature and extent of its psychological impact develops from the 
meaning each individual attaches to their skin state, which may in tum affect their 
interpretations of the reactions of those around them. Cash (1990), Cash & Labarge, 
1996 and Lansdown, Rumsey, Bradbury, Carr & Partridge et al. (1997) proposed that 
stigmatizing experiences playa role in generating cognitive schema that relate to 
appearance anxiety. Repeated stigmatizing experiences alter cognitive responses, 
sometimes leading to benign responses being perceived as hostile and mediating the 
association between disease severity and patients' distress (Vardy et al., 2002). 
Resulting beliefs may set up a cycle whereby skin disease negatively affects 
psychosocial functioning (Papadopoulos, et al., 1999a). Such cognitive mechanisms 
perpetuate body dissatisfaction and may lead to body shame. 
So how might shame be relevant to skin conditions? The concept of shame is useful in 
explaining distress as it affects psychosocial development, which has a profound impact 
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on cognitions, emotions and behaviour (Gilbert, 1998). A number of theorists have 
attempted to conceptualise shame in relation to the body; Papadopoulos, Aitken, Bor & 
• 
Legg, (2000) proposed an "intervening cognitive variable" which affects an individual's 
representations of their illness, while a direct connection between shame and body 
image disturbance has been proposed (Benrud-Larson, Heinberg, Boling, Reed, & 
White, 2003; Gilmore, 2000). Andrews, Mingyi & Valentine (2002) suggested that 
body shame generates avoidance and concealment behaviour and ruminative 
preoccupation with others' perceptions, in ways body dissatisfaction and negative self-
evaluation do not. The social visibility of skin conditions means that a vulnerability to 
shame and shame reactions appears likely. Such shame reactions may be crucial to the 
experience of skin distress (Ginsburg & Link's 1989; Jowett & Ryan 1985; Koblenzer, 
1997): Jowett & Ryan reported that 80% of people with skin conditions described 
shame and embarrassment as its worst aspects, while Ginsburg & Link reported 
participants' shame and embarrassment regarding their condition, reduced confidence 
and high incidence of depressive feelings regarding psoriasis. Andrews et al. 's (2002) 
suggested that shame plays a central role in the onset and course of depression for 
people with skin disease. 
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Shame has been defined as a multifaceted experience comprising social, self-evaluative, 
emotional, behavioural and physiological components (Gilbert, 2002). It has been 
considered largely as a trait, reflecting anxiety, anger and self-contempt, leading to 
negative automatic thoughts of the self as inferior, global and stable negative self-
evaluation and social avoidance behaviours. Cognitive theorists have emphasized the 
link between negative self-schema and stigma consciousness (Gilbert, 1998), associated 
with the loss of positive affect, while in psychotherapy, shame has been understood as 
the avoidance of social injury. Evolutionary psychologists have regarded shame as an 
adaptive exhibition of submissive behaviour in the presence of more dominant others 
(Gilbert, 1997) and in appearance terms, the avoidance of contamination of the social 
group. 
The role of shame in appearance dissatisfaction has attracted conceptual development. 
Kent (2000) and Kent & Thompson (2002) suggested a cognitive-behavioural model of 
the development and maintenance of disfigurement shame. This model details how self-
schema involving shame might generate social anxietY, sensitize the person to rejection 
and make negative experiences easier to recall. Kent & Thompson (2002a, 2002b) and 
Thompson & Kent (2001) implied that individuals living with disfigurement are at 
considerable risk of experiencing feelings of internal and external shame. This model 
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has been applied to dermatological conditions as a means of conceptualizing domain-
specific shame reactions, or "dermatological shame" (Kellett, 2002). If shame self-
schema may mediate skin conditions and self-perceptions, dermatological shame may 
represent a core factor in the development of psychological difficulties. Kellett 
hypothesized 3 types of schematic change that transform global schema into shame-
schema: schema reinforcement, schema attrition and schema vulnerability, arguing that 
dermatological shame can develop from early feelings of unattractiveness, negative 
social interaction or stigmatization (Gilbert 1992, 1998; Gilbert and Miles, 2002; Kellett 
and Gilbert, 2001). Kellett defined dermatological shame as "the inner emotional 
experience of the self as fundamentally unattractive to the self and others, vulnerable to 
rejection and put-down because of the state of the skin", illustrating its affective nature. 
Dermatological shame may be maintained, like other cognitive schema, by processes 
such as attentional bias, avoidance, concealment (Koblenzer. 1997) and shame 
compensation. Kellett reported that people with acne use behavioural avoidance 
strategies to curb feelings of shame, although this can lead to social withdrawal. 
Koblenzer proposed that patients often feel "dirty" and may withdraw for fear of 
arousing disgust and rejection, whilst Kellett (2002) suggested that acne sufferers avoid 
attending appointments with sources of help due to fear of exposure and shame. 
Thompson et aZ. (2002) found that women living with vitiligo felt different and 
88 
suggested that social support served to facilitate the development of coping strategies 
associated with feeling of acceptance. Others may perceive shame schema 
subconsciously and a negative reciprocal response elicited, perpetuating the shame 
experience. 
However, despite these findings and the current proliferation of psychodermatological 
literature, the conceptual status of dermatological shame remains tentative and little has 
been written regarding the role of shame in disfigurement (Thompson & Kent, 2001). 
This forms the basis of the study rationale. 
3 STUDY RATIONALE 
Although dermatological shame appears to be a domain-specific phenomenon, no 
corresponding measure currently exists. Therefore, this paper aims to construct a Skin 
Shame Scale (SSS), and test its underlying factor structure. It was necessary to ascertain 
whether dermatological shame is a unifactorial or multifactorial concept and 
correspondingly, whether behavioural aspects, such as avoidance represent distinct 
factors. These questions were addressed though iterative factor analytic investigation. 
89 
There are a number of theoretical and clinical justifications for this study. Although 
there is growing recognition of the psychological impact of skin disease, there is less 
theoretical explanation as to how and why distress occurs. The effects of skin conditions 
are poorly understood, because the mechanisms leading to dermatological distress have 
not been investigated from a perspective based on psychological theory. The 
development of appearance distress measures has usually relied on empirical research, 
descriptive studies and expert opinion (Barankin & DeKoven, 2002), to the detriment of 
theoretical advancement. A number of existing generalised and body shame measures 
and measures of distress regarding appearance exist (Tangney, 1996), but none focus 
specifically on dermatological shame. Shame measures were of limited applicability as 
they contain no skin-specific items. The Derriford Appearance Scale (DAS-59: Carr et 
al., 2000) assesses the distress experienced by people with appearance difficulties by 
general, social, sexual, body and facial factors, but does not pinpoint shame, focusing 
on self-consciousness, which may not possess the same affective intensity as shame. 
Bodily, rather than skin, shame is one of eight shame aspects explored in the Experience 
of Shame Scale (ESS: Andrews et al., 2002). The SSS was constructed to compliment 
what Carr et al. described as the current paucity of outcome measures that has limited 
treatment evaluation 
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In order to address this, this study was theory-driven. Initial SSS items were based on 
the model of dermatological shame (Kellett, 2002), developed from the cognitive-
behavioural model of disfigurement (Kent & Thompson, 2002). A voidance and 
concealment behaviours were included as protective strategies against shame-triggering 
event, while items relating to stigma reflected their role in generating shame-schema. 
This was supported by the literature on external shame and the fear of others' judgment 
(Gilbert, 1998, Kent & Thompson 2002; Thompson & Kent, 2001). As psychological 
assessments and interventions have been indicated increasingly in dermatology, this 
scale was designed equally for its potential clinical utility. 
4 RESEARCH AIMS 
Therefore, the present study had the following research aims: (1) to construct the SSS, 
by the systematic selection of items that contribute significantly to dermatological 
shame; (2) to administer it to a large dermatological population; (3) to identify its 
underlying factor structures; (4) to begin to assess its internal reliability and (5) to begin 
to test its concurrent and divergent construct validity and criterion validity against other 
measures. 
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4.1 Hypotheses 
In order to determine the external validity of the SSS, six hypotheses were developed 
from the research aims. 
1 The SSS will be moderately positively correlated with the Hospital Anxiety and 
Depression Scale (HADS: Zigmond & Snaith, 1983, see Appendix 3) and the 
Internalized Shame Scale (ISS: Cook, 1994, see Appendix 4). For the purposes of this 
study, the criterion ofr = 0.60 or above was used to describe a moderate correlation and 
applied to established scales and the SSS. 
2 Women will score more highly on the SSS, HADS and ISS than men. 
3 Patients with visible skin conditions (face or hands) will score more highly on 
the SSS, HADS and ISS than those with less visible conditions (body). 
4 Self-reported severity (face, hands, body and total) will correlate more strongly 
with SSS, HADS and ISS than clinician-reported severity. 
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5 Patients will rate their skin conditions more severely than clinicians (face, hands, 
body and total severity). 
6 Older patients will score less highly on the SSS, HADS and ISS than younger 
patients. 
The research aims and hypotheses were addressed by the following procedures. 
4.2 Construction of the SSS 
The first stage in developing the SSS involved the selection of 30 items contributing to 
dermatological shame. The aim was to reduce this scale to a clinically useful index of 
20-24 items. 
4.3 Item generation 
Generation methodology was used to develop items for the initial 30-item SSS 
(Wackerbarth et al., 2002). This method involved collating potential items from 
multiple sources and employing systematic analysis to identify the most relevant. In 
psychodermatological research such a strategy has previously been used by Jowett & 
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Ryan (1985) to generate statements about individuals' self-consciousness regarding 
their skin. 
Items related to skin shame were collated from: (a) interviews with dermatologists: (b) 
psychodermatological researchers and (c) existing measures, including the Experience 
of Shame Scale (ESS: Andrews et al., 2002) and The Derriford Appearance Scale 
(DAS-59: Carr et al., 2000). 
The initial item list was analyzed by a multi-professional panel to enhance the 
comprehensiveness of items generated, and to minimise the omission of crucial items. 
Items within the initial 30-item SSS were developed under the factors suggested by the 
cognitive model of dermatological shame (Kellett, 2002), to enhance construct and 
content validity. These factors were envisaged as; "affect", "behaviour", "cognitions", 
"stigma" and "pride". Items were then ordered by these five factors to avoid generating 
a response set and an initial SSS containing 30-items formed. The SSS assessed 
participants' responses based on their feelings over the last week. Participants were 
asked to respond to items on a 5-point Likert-style response scale (Likert, 1932) ranging 
from "Never" to "Always". The initial30-item initial SSS can be found in Appendix 5. 
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4.4 Face and Content Validity 
In order to increase face and content validity and identify floor and ceiling effects, the 
initial SSS was piloted with 5 people with skin conditions. Respondents completed the 
questionnaire and were invited to comment on the items, instructions and response 
format. Problematic items were rejected and minor modifications made to the wording 
of remaining items and the revised 30-item SSS used in the study. 
5 METHOD 
5.1 Research Approval 
In order to proceed with the study, ethical Approval was obtained from the University 
of Sheffield's Research Sub-Committee (see Appendix 6) and from Barnsley Research 
Ethics Committee (see Appendix 7). Research indemnity was obtained from the Risk 
Management Department at Community Health Sheffield (see Appendix 8) and non-
clinical trial insurance from the Department of Finance at the University of Sheffield 
(see Appendix 9). A target journal for publication was identified and the guidelines 
included in Appendix 10. 
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5.2 Participants and procedure 
Potential participants were those with chronic skin conditions attending initial and 
follow-up outpatients' appointments at Bamsley District General Hospital dermatology 
department, over a 6-month period (September 2003 to February 2004). A consultant 
dermatologist or nurse asked each participant whether they would like to take part in a 
study regarding how people felt about their skin. If they consented, they were offered 
the Research Information Sheet (Appendix 11). If, on reading this, they agreed to take 
part in the study, each participant completed the Research Consent Form (see Appendix 
12). 
One hundred and sixty-two participants completed a booklet of questionnaires, 
including the initial 30-item SSS, which were used in subsequent data analysis. 
Participants were given the option of completing this whilst at the clinic in the presence 
of the principal researcher, or returning it in a prepaid envelope. 
5.3 Questionnaires 
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The questionnaire booklet contained 4 measures: (1) the initial SSS; (2) a subjective 
index of the participant's skin disease measured on a scale of 1 to 10 (1 = "practically 
clear" to 10 = "in a bad state", called "A study into how you feel about your skin", see 
Appendix 13); (3) the Hospital Anxiety and Depression Questionnaire and (4) the 
Internalized Shame Scale. Simultaneously, each participant's nurse or consultant 
completed the same index of the participant's skin disease based on their clinical 
observations, called the Clinician Report Form (see Appendix 14). 
The HADS is a well-validated measure for assessing anxiety and depression (Lewis & 
Wesley, 1990) and has been utilized in psychodermatological research as a predictor of 
mood (Fortune et az', 2002a; Fortune, Richards, Kirby, Bowcock, Main, et 01., 2002b; 
Kellett & Gawkroger, 1999; Kirby et 01., 2000; Richards et 01., 2001), functional status 
and anxiety and depression in psoriasis (Fortune et 01., 2002a; Scharloo, Kaptein, 
Weinman, Hazes, Willems, 1998; Scharloo, Kaptein, Weinman, Bergman, Vermeer et 
01., 2000). It has also been shown to be unbiased by physical symptomology, which was 
crucial in this setting. Cross-sectional research has demonstrated high reliability and 
validity and significant correlations between shame and depression measures such as the 
HADS. The ISS has been shown to have high reliability and construct validity (Cook, 
1996; Cook & Campbell, 1979) and provided an additional measure of self-esteem, as it 
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includes the items comprising the Rosenberg self-esteem scale (RSES: Rosenberg, 
1965). A score of 50 or over is indicative of possibly problematic levels of shame. The 
ISS has shown impressive reliability with clinical samples of people with anxiety 
(Cook, 1996; Turner & Lee, 1998). 
Background data were also obtained pertaining to dermatological diagnosis and 
associated duration. Data from all 4 questionnaires in the booklet, along with those from 
the Clinician Report Form, were then entered into a database. SSS data were analyzed 
using principal axis and item analysis, as described below, and a final 24-item SSS 
constructed and used to test the research hypotheses. 
6 RESULTS 
Firstly, this section reports the descriptive statistics of the study sample. The factorial 
validity of the SSS is then reported, the specific research hypotheses tested and 
inferential analysis undertaken. 
6.1 Overview of Results 
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Data analysis was conducted using the computer package SPSS version 11 to explore 
the relationships between variables, using the range of statistical tests described below. 
To reduce the probability of type 2 errors in this exploratory study, a significance level 
ofp=O.05 was used throughout the analysis. A table of the descriptive statistics of major 
variables can found in Appendix 15. All values are rounded up to 2 decimal places. 
Participant characteristics are described below. 
6.2 Participant Characteristics 
The sample comprised of 101 women (62.3%) and 61 men (37.7%) with a mean age of 
46 (SD = 18.95). The most prevalent self-reported skin conditions were psoriasis (55 
participants, 34% of total sample), eczema (43,26.5%) and acne (15, 2.3%) and their 
mean duration was 14.23 years (SD = 15.42). The mean prevalence of both depression 
and anxiety within this sample was approximately 13 %. Table 2 below indicates that, 
even when allowing for the greater ratio of women, this sample contained a greater 
proportion of females with acne than males, in contrast with existing studies (Kellett & 
Gawkroger, 1999). 
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6.3 Table 2: Dermatological diagnoses and gender 
Gender Male % of subset Female % of subset 
Condition 
Psoriasis 25 45% 30 55% 
Eczema 15 35% 28 65% 
Acne 3 20% 12 80% 
6.4 Non-respondents 
It was not possible to gather data on non-respondents, though the consultants reported 
anecdotally that they tended to be male and have lower educational status than 
participants. 
6.5 Data analysis 
Data analysis then proceeded in 4 stages: preliminary construct and criterion validity 
testing of the initial SSS using principal axis analysis, construction of the final 24-item 
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SSS, reliability testing of the final SSS, and investigation of related hypotheses using 
independent t-tests and correlational methods. 
Initial inspection of the data suggested all variables were normally distributed, apart 
from the SSS total score, which was negatively skewed, implying that the distribution 
had a preponderance of high values. However, as the. skew was not severe (Kolgorov-
Smimov = 0.20), it was decided not to transform the data, as this was likely to make 
interpretations of results problematic. The Kaiser-Meyer-Olkin measure suggested that 
sampling adequacy was satisfactory (0.890) and Bartlett's test of sphericity was 
significant (approximate chi-square 1781.20, significance 0.00). 
Exploratory factor analysis (EF A), also termed principal axis analysis, was utilized to 
identify the latent variables possibly underpinning dermatological shame. This form of 
factor analysis is often used when attempting to understand underlying scale structure, 
which represented a central research aim (Brown, 1990; Tabachnick & Fidell, 1999, 
2001). This sample satisfied the statistical rule of 150 participants for a principal axis 
analysis (Tabachnick & Fidell, 1999). Therefore, a frank exploration of the construct 
validity of the initial SSS was possible, in order to develop a final version of the scale. 
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6.6 Scale construction 
6.6.1 Validity of initial SSS 
In order to address the central research aim, the validity of the initial SSS was explored 
by means of principal axis analysis, item analysis and hypotheses testing for concurrent 
criterion validity. 
6.6.2 Principal axis analysis 
A principal axis analysis was carried out on data from the 30 initial SSS items, 
employing the Kaiser-Guttman criterion, requiring eigenvalues to be greater than 1 for 
factor retention. In all cases, an iterative factor extraction method was used as factors 
were likely to be correlated above r = 0.40 (Tabachnik & Fidell, 1999,2001). 
Inspection of the correlation matrix between the items suggested that the SSS was 
factorable, and therefore further analyses feasible, because a reasonable number of 
items exceeded DAD and Bartlett's sphericity test indicated that the null hypothesis that 
the variables were uncorrelated could be rejected. 
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Unrotated EF A found 8 factors exceeding 1.0, but the scree plot was ambiguous. The 
unrotated factor matrix of the 30 variables suggested that, while the majority of items 
loaded heavily onto factor 1, some cross-loaded moderately onto other factors. The EFA 
was therefore re-run once, using an orthogonal varimax rotation and once with an 
oblique rotation using the oblimin method. The varimax rotational technique has the 
advantage of simplifying factors by making high loadings higher and minimizing low 
loadings, thereby making the correlations between factor variables less ambiguous. 
Principal axis factoring with the varimax method obtained 8 factors with eigenvalues 
above 1, accounting for 66.46% of the total variance, of which a simple structure of 4 
factors accounting for 51.20% seemed to describe the data adequately (Streiner, 1994). 
Although a 7 or 8-factor solution may have accounted for a greater proportion of 
variance, the 4-factor interpretation was more parsimonious. The eigenvalues above 1 
for each factor, identifying identify factors that explain a significant proportion of 
variance, are represented in Table 2 and a more detailed representation of the factor 
loadings >0.4 appears in Table 3, illustrating which items constituted the factors. 
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6.6.3 Table 2: Eigenvalues above 1 
Extraction Sums of Squared Rotation Sums of Squared 
Factor Initial Eigenvalues Loadlnga Loadlnga 
%of Cumula %of Cumula %of Cumula 
Total Variance tlve% Total Variance tlve% Total Variance tlve% 
1 10.13 
33.794 33.794 9.718 32.393 32.393 4.238 14.128 14.128 
8 
2 2.096 6.988 40.781 1.666 5.555 37.948 2.682 8.941 23.069 
3 1.737 5.789 46.570 1.268 4.224 42.174 2.194 7.314 30.383 
4 1.387 4.622 51.192 .914 3.045 45.219 1.801 6.004 36.387 
5 1.247 4.189 55.381 .784 2.615 47.834 1.784 5.947 42.334 
6 1.187 3.956 59.337 .712 2.373 50.206 1.687 5.622 47.956 
7 1.108 3.694 63.031 .649 2.162 52.368 1.017 3.390 51.346 
8 1.028 3.424 66.456 .628 2.092 54.460 .934 3.114 54.460 
6.6.4 Table 3: Factor Matrix (items contributing to factors emboldened) 
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Affective Skin Stigma Behavioural 
avoidance pride avoidance 
Summary of Item 1 2 3 4 5 6 7 8 
14-worry 
.743 
15 - thinking 
.630 
about 
26 - despondent 
.598 
13 - hiding 
.589 
11-ashamed 
.588 
21 - worrying 
.550 .427 
7 - different 
.533 .403 
27 - avoid people 
.504 .414 touching 
3 - unattractive 
.439 .418 
12-avold 
.439 
socialising 
5 - rules life 
.407 .405 
8 - beautiful 
.776 
23 - as attractive .638 
24-1 avoid 
.624 touching 
16 - proud 
.412 .608 
28 - feel good 
6 - others stare 
.644 
4-avold 
.517 
undressing 
19 - avoid hoping 
20 - avoid contact 
.644 
10 - like partner 
.497 touching 
2 - avoid mirror 
.573 
25 - others avoid 
.548 touching 
17-avold 
.509 discussing 
9-avold 
.465 
treatment 
1- learnt to live 
.640 
18 - people accept 
.505 -.417 
30 - one aspect 
.489 
22 - contagious 
.823 
29 - checking 
.624 
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As in most exploratory analyses, factor 1 accounted for considerably more variance than 
subsequent factors (Floyd & Wi daman, 1995). The first factor had an eigenvalue of 
10.14 and accounted for 33.79% of the variance, comprising of II items pertaining to 
the negative affective components of skin distress, such as, "I am ashamed of my skin", 
"I worry about how my skin appears". Items were combined within a scale labelled 
affective avoidance. 
The second factor accounted for 6.99% of the item variance (eigenvalue = 2.10) and 
comprised of 4 items concerning positive perceptions of skin disease such as, "My skin 
is as attractive as other peoples''', and "I am proud of my skin". These items produced a 
scale of skin pride. 
The third factor (eigenvalue = 1.74, 5.80% of variance) contained 6 items relating to 
social avoidance, although 4 of these were cross-loaded onto factor 1, such as "others 
stare at my skin" and "I avoid undressing in front of people", behaviour, which were 
combined to produce a scale of stigma. 
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Factor 5, containing 4 items and accounting for 4.19 of variance (eigenvalue = 1.26) 
was comprised of items relating to avoidance behaviour, such as "1 avoid 
discussing/touching my skin" and produced a scale of behavioural avoidance. 
Thus, the proposed factor structure was not obtained fully, although 4 of the suggested 5 
factors of affect, skin pride, stigma and behavioural avoidance were identified. The 
anticipated cognitive factor of skin distress was not found in this study. 
6.6.5 Item analysis 
Item-total correlations using Cronbach's Alpha were then applied to the identified 
subscales, so that those items accounting for the most variance could be retained and 
others excluded from the final SSS. Those sub-scales comprising of 5< factors were 
then tested for internal reliability; this criterion was employed as factors with less than 5 
items are considered less reliable in EF A. Factors 1 and 3 were tested, therefore, and 
found to have good reliability of 0.92 and 0.84 respectively. Reliability analysis 
indicated that these factors had adequate internal reliability of 0.6 or over. It was then 
decided to examine factors 2 and 5, in case their internal consistency might be 
improved. Item-subscale analysis indicated that the consistency of factor 2 was high 
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(0.79) and that it could be improved in factor 5, from 0.68 to 0.70 by deleting factor 9, 
"I avoid getting treatment for my skin". However, this was not considered a significant 
improvement and the item was retained. The increase in alpha deriving from deleting 
this item would have been less important than retaining it within length of the scale. 
Thus, the sub-scales were not amended by item analysis. 
When factors were examined for cross-loadings, 4 of the items from factor 3, stigma, 
were found to cross-load onto factor 1, affective avoidance, albeit with weaker loadings. 
However, these factors were retained, as it was felt that a degree of cross-correlation 
between them might be expected. EF A and face validity were then used to exclude 
redundant items, as described below. 
6.6.6 Data reduction and final version of SSS 
However, EF A helped identify 2 items that loaded onto a factor containing only 1 item 
(items 22, "people think my condition is contagious" and 29, "I take every chance to 
check my skin) and 2 that did not factor (19, "I've given up hoping my skin will 
improve" and 28, "I avoid people touching my skin". Item 1 0, "I like my partner to 
touch my skin intimately", was removed as it was not applicable for all participants. 
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Therefore, these were removed from the final version of the SSS, along with item 21, "I 
worry about how my skin appears", as this replicated item 14, "1 worry how my skin 
looks to others", but did not load as highly onto factor 1. Also, it cross-loaded onto 
factor 3. Thus, the final SSS was comprised of 24 items and can be found in Appendix 
16. The 4 factors were intercorrelated in the factor correlation matrix in Table 4 below, 
which suggests a moderate degree of independence between the factors. 
6.7 Table 4: Factor Correlation Matrix 
Factor 1- Factor 4-
Affective Factor 2- Factor 3 - Behavioural 
avoidance Skin pride St!9.ma avoidance 
Factor 1 - Affective Pearson Correlation 1 .111 .073 .049 
avoidance Sig. (2-tailed) 
.161 .355 .535 
Factor 2 - Skin Pearson Correlation .111 1 .024 .065 
pride Sig. (2-tailed) 
.161 .763 .414 
Factor 3 - Stigma Pearson Correlation 
.073 .024 1 .029 
Sig. (2-tailed) 
.355 .763 .719 
Factor 4- Pearson Correlation 
.049 .065 .029 1 
Behavioural Sig. (2-tailed) 
.535 .414 .719 avoidance 
6.8 Reliability of the final SSS 
Two methods of internal consistency reliability estimates were employed; Cronbach' s 
coefficient alpha (Cronbach, 1951), which is a multipoint variation of the Kudor-
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Richardson formula (Nunnally, 1970) and split-half reliabilities (Spearman-Brown 
formula). These methods showed that the full-scale initial SSS had good reliabilities of 
0.92, and 0.88 respectively, placing them in the "high" correlation domain ofr = 0.80 or 
above (Anastasi, 1988). Item-full scale testing using an inclusion/deletion criterion of 
0.5 showed that, as internal reliability was sufficiently high, no items needed to be 
removed on this criterion to increase it further. 
6.S.1 Concurrent criterion validity of final SSS 
External-related criterion validity (Aitken, 1996) of the SSS was tested by using 
Pearson correlation coefficients (r) between full-scale SSS scores and HADS and ISS 
scores as continuous variables, as the external criterion for the presence of 
psychological distress. The full scale SSS correlated significantly at the p = 0.01 level 
with the HADS depression (r = 0.41), HADS anxiety (R = 0.52), HADS total score (r = 
0.52) and ISS shame (r =0.57), suggesting low to moderate external criterion validity, 
while the final full-scale SSS correlated negatively with the ISS self-esteem subscale at 
the 0.01 significance level (r = -0.47, p = 0.000). These results supported hypothesis 1, 
suggesting that the SSS was closely related to anxiety. 
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Correlational analysis showed that, of the 4 factor sub-scales, factor 1, representing 
affective avoidance, correlated moderately with the HADS total and anxiety scales and 
with the ISS shame scale, but was negatively correlated with the self-esteem sub scale of 
the ISS (r = -0.29, P = 0.000). As this factor explained a greater proportion of variance 
than other factors, it was used in subsequent criterion analyses. As expected, item 14, 
with the highest loading on factor 1, correlated most strongly with the HADS total and 
anxiety scales and ISS shame scale. It was significantly, though moderately correlated 
with the HADS depression scale. A table of correlations between the initial SSS items, 
HADS sub and total scales and the ISS can be found in appendix 17, illustrating the 
satisfactory number of significant correlation between the final 24 items of the SSS, the 
HADS sub and total and ISS total scores. 
6.9 Hypotheses testing 
Hypothesis testing was then carried out using the final 24-item SSS. The external 
validity testing demonstrated that the full-scale SSS was indeed moderately correlated 
with the HADS depression, anxiety and total scores and negatively correlated with the 
ISS self-esteem score at the 0.01 significance level (r = -0.47). Factor 1, affective 
avoidance, correlated with the HADS total score at the 0.05 level (r = 0.18) and even 
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more highly with HADS anxiety (r = 0.41, P = 0.01). Hypothesis 1 was therefore 
upheld. When equality of variances were assumed according to Levene's test, 
independent t-tests showed that women scored more highly than men on the full-scale 
SSS and affective avoidance subscale at p = 0.01 and on the HADS total score and ISS 
shame scale, as shown in table 4 below. This result occurred despite there being no 
significant difference in self-reported total disease severity scores. Hypothesis 2 was, 
therefore, upheld. 
6.9.1 Table 5: Mean differences in scores by gender 
Gender Mean difference T score Significance 
Scale 
Final full-scale 6.83 2.40 0.17 
SSS 
Factor 1 affective 0.32 2.21 0.28 
avoidance 
HADS depression 1.93 1.92 0.06 
HADS anxiety 1.04 2.91 0.004** 
HADS total 3.09 2.78 0.006** 
ISS shame 9.97 3.12 0.002** 
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*p<0.05 
**p<O.Ol 
Thus, table 5 highlights the significant differences between male and female participants 
in terms of their anxiety and shame scores. Using correlational methods, patients with 
visible skin conditions on the face and hands were not found to have significantly 
higher SSS scores than those with skin conditions on the body, by either self or clinician 
report. In fact, severity scores for face, body and total severity were found to be very 
similar according to clinician and self-report, hand severity scores being slightly lower. 
Therefore, hypothesis 4 was rejected. Correlational methods did indeed demonstrate that 
self-reported severity scores correlated significantly better with the full-scale SSS, 
affective avoidance subscale, HADS total and subscales and ISS shame scale than 
clinician-reported scores. Self-reported facial, body and total severity also correlated 
with the SSS at the 0.01 level (r = 0.32, 0.32 and 0.40 respectively). However, full-scale 
SSS scores showed no significant relationship with clinician-rated severity. As 
anticipated, self-reported total severity correlated positively with ISS shame (r = 0.29) 
and negatively with the self-esteem subscale of the ISS (r = -0.29), both at the 0.01 
significance level, whereas there was no significant correlation between clinician-
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reported severity, the ISS or self-esteem. Hypothesis 5 that self-reported severity is 
better correlated with distress scores than clinician ratings was therefore upheld, as 
illustrated by the higher number of significant correlations in table 6 below. 
6.9.2 Table 6: 
Correlations between self and clinician-reported disease severity ratings and 
distress 
Correlation (r) Self-report Clinician-report 
Scale 
Final full-scale 0.40* 0.10 
SSS 
Factor 1 - affective 0.13 -0.10 
avoidance 
HADS depression 0.25* -0.01 
HADS anxiety 0.30* -0.04 
HADS total 0.31* -0.05 
ISS 0.29* -0.10 
*p = 0.05 indIcates sIgruficant dIfference between scores 
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Pearson's analysis indicated a correlation ofr = 0.46 between total severity as scored by 
the patient and clinician, which was significant at the 0.01 level, meaning that the null 
hypothesis could not be rejected. Spearman's correlations between participants' ages as 
a continuous variable and SSS scores showed that a negative correlation existed at r = -
0.18, this correlation being significant at the p = 0.05 level, upholding hypothesis 6. An 
overview of both the EFA and hypotheses testing will be offered below. 
7 DISCUSSION 
The aim of this study was to construct a measure of dermatological shame and begin 
preliminary investigations into its validity and reliability. This section describes the 
study's implications and how the results relate to the research aims and hypotheses. 
Methodological, theoretical and clinical considerations and will also be discussed, 
7.1 Implications of the present study 
This study is the first to attempt to develop a psychodermatological measure pertaining 
to shame. Models of shame relating to dermatology and disfigurement (Kellett, 2002; 
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Kent & Thompson, 2002) were utilized to construct a scale that was subjected to 
principal axis analysis to inform its theoretical construct. This demonstrated that the 
measure consisted of more than one subscale, rather than supporting an independence 
model that all variables showed independence, i.e. were unrelated (Tabachnik & Fidell, 
1999). Validity and reliability analyses suggested that the SSS is a promising 
psychometric index of psychodermatological distress, which is related to the concept of 
dermatological shame. The factor structure extracted illustrated that the SSS had robust 
construct validity, and reflected the anticipated factors based on cognitive models of 
disfigurement, although it did not replicate the proposed five factors model, due to the 
cognitive aspect of dermatological shame failing to factor effectively. 
In terms of external criterion validity, the final full scale SSS correlated well with the 
HADS and ISS. A moderate correlation between, the affective avoidance factor, HADS 
sub and full scales and the ISS was also found. Both the full-scale SSS and the affective 
avoidance subscale showed strong negative correlations with the ISS self-esteem 
subscale, suggesting discriminative validity. Content validity was enhanced by item 
generation, each item being endorsed by an adequate proportion of participants (5% or 
more). 
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The mean prevalence of clinically significant depression and anxiety within this sample 
(approximately 13 %) was comparable with that found in one existing studies (Picardi et 
aI., 2003) but lower than the average of around 24% across others. Using a cut-off of 11 
on either HADS subscale (Love et aI., 2002), ten participants indicated depression 
(6.17% of sample), of whom 8 were female (80% of this subgroup), while 31 reported 
scores suggestive of clinical anxiety (19.14%), 24 being female (77.42% of subgroup). 
It is possible that existing studies included patients with some degree of pre-existing 
morbidity, or that their results related to different assessment tools, for example, Picardi 
et al. (2000,2003) employed the GHQ-12 (Goldberg, 1972), which may have yielded 
differing prevalence. Like existing research (Schmid, 1996), this study illustrated the 
higher prevalence of affective disorders in women than men, especially of anxiety and 
internalized shame, despite their similar disease severity scores. The higher prevalence 
of anxiety in this sample suggested that it may represent a greater component of skin 
distress than depression, while the high correlation between ISS shame and HADS 
anxiety suggested that skin distress relating to shame-proneness correlated highly with 
anxiety responses in this sample. ISS shame was also highly correlated with HADS 
depression, indicating the salience of low mood in skin-related distress. Other 
participants may have been experiencing significant but sub-clinical levels of skin-
related psychological distress, which is perhaps more reflective of the 24-33% of 
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dermatology patients with psychosocial difficulties suggested by Gupta & Gupta 
(2001 a, 200 1 b) and Ginsberg (1996). It is possible that participants had pre-existing 
anxiety and depression that were not due to skin issues, which may have compounded 
their skin-related distress. 
In terms of hypotheses, the salience of gender on skin-related distress levels was borne 
out, while the effects of disease location and age were less conclusive. The sample 
contained a greater proportion of women, which appears typical of dermatology 
outpatients' services (personal communication, 16th December, 2003). However, the 
results suggested that they experience more skin-related distress and anxiety than their 
male counterparts, independent of disease severity. Testing of the disease location 
hypotheses suggested that the face and body were more closely associated with skin 
distress than the hands, which was consistent with findings that facial symptomology 
appear to heighten psychological distress (Papadopoulos et ai., 2000). The relatively 
small size of the hands may suggest that disease coverage is more strongly linked with 
distress than location. The result indicating that age was negatively correlated with skin 
distress, perhaps supports the notion that aging, although not altogether negating skin-
related distress, is predictive of adjustment. The significance of the relationship between 
self-reported disease severity and skin-related distress was strongly upheld and appears 
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to endorse the idea that sUbjective perceptions are crucial in determining the extent and 
nature of distress (Scharloo et ai., 1998). 
It would be premature to assume that the mediating mechanisms of skin dress leading to 
psychological distress are exclusively shame-based as no causal inferences can be made 
in a cross-sectional study. However, these results do suggest that women with skin 
conditions may be more shame prone than men and that self-reported severity is a better 
predictor of skin distress than clinician ratings. The high prevalence of anxiety also 
reflects the literature around the clinical assessment of dermatology outpatients 
(Richards et ai., 2003). 
7.2 Theoretical issues 
These results suggest that the distress felt by some people with skin conditions is 
closely related to cognitive models of shame, but suggested that many people with skin 
conditions, even those who are distressed, undergo a degree of adjustment to their skin 
condition and retain some sense of pride in their skin. This may be because not all areas 
of their skin are affected by the disease. It could be argued on the basis of this study, 
that both anxiety and shame mediate the psychological effects of skin conditions, which 
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is moderated by others' reactions in the form of stigma, and that pride and adjustment 
may protect against the development of skin distress. 
Using items from different shame dimensions demonstrated that people living with skin 
conditions could experience shame in one or more, but not all, domains. This 
endorsement of the conceptual status of dermatological shame upholds Andrews el al. 's 
(2002) suggestion that it is valuable to divide shame into domains for research purposes 
and it is worthy of further exploration regarding the relationship between skin 
conditions and distress. A cognitive factor describing, perhaps, skin checking 
compulsions and fear of exposure was anticipated but not found, perhaps because the 
initial SSS contained insufficient items to tap into this phenomenon and the future 
expansion of cognitive items might prove useful. Despite this, the final SSS appears a 
meaningful measure of skin distress that provides some explanation of the individual's 
experiences, rather than being explicitly and therefore narrowly symptom-based. 
7.3 Clinical implications 
The final SSS is potentially a clinically informative, brief and multidimensional 
screening tool that may help clinicians to target the specific distress of people with skin 
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conditions with individualised interventions. In conjunction with clinical assessment, 
the SSS may be able to differentiate individuals in terms of psychological interventions, 
thus addressing Carr et al. 's (2000) call for clinically and psychometrically robust 
scales. 
7.4 Methodological Limitations 
Measure, participant and sample characteristics represented methodological issues of 
concern in this study. Perhaps the most significant was that the SSS was not subjected 
to test-retest reliability analysis, as participants were actively undergoing treatment that 
was likely to have confounded these results, although its reliability was examined by 
other means. There is a risk in health settings that the HADS depression score may have 
been confounded by physiological fatigue symptoms, while the ISS lacked face validity 
with participants. The assessment of shame might be improved by the inclusion of an 
alternative measure, such as Andrews et al. 's Experience of Shame Scale (2002). It is 
also possible that nurses and dermatologists may have provided different interpretations 
of disease severity, which might be controlled for by using reports from one 
professional group. The issue of common method variance must also be considered 
when evaluating external validity analyses of the fmal SSS. 
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8 CONCLUSION 
This study appears to have largely addressed its research aims of constructing the SSS, 
administering it to a large dermatological population, and beginning to examine its 
psychometric properties though further investigations into aspects of its reliability and 
validity are necessary. The development of the SSS has begun to consolidate the theory 
of dermatological shame and added to the understanding of the mechanisms of skin 
distress. The final version of the SSS is brief and seemed meaningful to participants and 
appears promising as a measure of psychological distress in dermatological conditions. 
Further research into the emotional and psychological factors surrounding chronic skin 
disease demands well-controlled empirical investigation. It is hoped that the 
development of this measure might widen the field of clinical enquiry into the 
psychological distress reported by dermatology patients and consolidate the breadth of 
measures available to evaluate interventions. 
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Here is a list of statements describing feelings and experiences about your skin that you 
mayor may not have. Many people have had these feelings at some time while others 
will rarely or never have had these feelings. Please try to be as honest as you can in 
responding to each statement. 
Please read each statement carefully and circle the number on the right that best 
describes how often it has applied to you over the last week. 
Never rarely sometimes often always 
1. I've learnt to live with my skin condition 2 3 4 5 
2. I avoid looking at my skin the mirror 2 3 4 5 
3. My skin looks unattractive 2 3 4 5 
4. I avoid undressing in front of people 2 3 4 5 
5. My skin condition rules my life 2 3 4 5 
6. Others stare at my skin 2 3 4 5 
7. My skin makes me different 2 3 4 5 
8. My skin is beautiful 2 3 4 5 
9. I avoid getting treatment for my skin 2 3 4 5 
10. I like my partner to touch my skin intimately I 2 3 4 5 
II. I am ashamed of my skin 2 3 4 5 
12. I avoid socialising because of my skin 2 3 4 5 
13. Hiding my skin makes me feel better 2 3 4 5 
14. I worry how my skin looks to others 2 3 4 5 
15. I find myself thinking about my skin 2 3 4 5 
16. I am proud of my skin 2 3 4 5 
17. I avoid discussing my skin 2 3 4 5 
18. I believe that people accept my skin 2 3 4 5 
19. I've given up hoping my skin will improve 2 3 4 5 
20. I avoid intimate contact because of my skin 2 3 4 5 
21. I worry about how my skin appears 2 3 4 5 
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22. People think my condition is contagious 2 3 4 5 
23. My skin is as attractive as other peoples' 2 3 4 5 
24. I avoid touching my skin 2 3 4 5 
25. I can control my skin condition 2 3 4 5 
26. I feel despondent about my skin 2 3 4 5 
27. I avoid people touching my skin 2 3 4 5 
28. I feel good when people touch my skin 2 3 4 5 
29. I take every chance to check my skin 2 3 4 5 
30. My skin condition is only one aspect of me 2 4 5 
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APPENDIX 11: RESEARCH INFORMATION SHEET 
INFORMATION SHEET 
A STUDY INTO HOW YOU FEEL ABOUT YOUR SKIN 
Who is conducting this study? 
Caroline Scott, a Trainee Clinical Psychologist at Sheffield University, in collaboration 
with Drs David Gawkroger, Ruth Sabroe and Glenda Sobey, Consultant Dermatologists. 
What is this study for? 
This study will look at the relationship between skin condition and how they can make 
people feel. Your responses will be used to construct a questionnaire. 
What are the benefits of this study? 
The questionnaire will be useful in helping researchers try to understand how people 
feel about their skin and improve treatment. 
What will be involved if I agree to take part in the study? 
This study will ask you questions about how you feel about your skin condition. The 
questions are written as statements. You can hand it back to Caroline Scott in the clinic, 
or complete it in your own time and return it in the envelope provided. 
Do I have to take part? 
No. You are free to refuse to take part in this study. Your treatment will not be affected 
many way. 
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Can I withdraw from the study? 
Yes. You can do this at any time and you do not have to give a reason. 
What other information will be collected in the study? 
You will be invited to complete 3 other short questionnaires. In all, the 4 questionnaires 
should take about 15-20 minutes of your time. 
Will the information I give be confidential? 
Yes. All answers in the questionnaire are treated with the strictest confidence. Your 
anonymous ID number means no names are used in reports, so no one can be identified. 
All questionnaires will be stored securely. We are interested in people with skin 
conditions as a group, not as individuals. 
What should I do if I need to talk with someone? 
If completing the questionnaires makes you want to talk to somebody, please contact 
the skin clinic to arrange an appointment or arrange an appointment with your GP. 
What if I'm feeling upset? 
If taking part in the study suggests you are very depressed, or you tell us this, the 
researcher will encourage you to discuss this with your consultant. In extreme cases, if 
you tell us about suicidal feelings, the researcher will advise you strongly to tell your 
consultant. If you choose not to, the researcher will seek your permission to inform the 
consultant before doing this on your behalf. If you do not give your permission, the 
researcher may choose to inform the consultant for your own safety. 
What if I would like more information? 
Please contact C SCOTT 0114 2226576 
(Trainee Clinical Psychologist) 
DR R SABROE 01226 320 417 
(Consultant Der11Ultologist) 
DR SCKELLETT 01226 777914 
149 
(Clinical Psychologist/Research Supervisor) 
Dr A THOMPSON 01142226570 
(Senior Clinical Psychologist/Research Supervisor) 
DR GERRY KENT 0114 2226570 
(Senior Clinical Psychologist/Research Supervisor) 
Dr Sabroe is a Consultant Dermatologist at Barnsley District Hospital. Caroline 
Scott is supervised in this study by Dr Kellett, Dr Thompson and Dr Kent. Dr 
Kellett is a Senior Clinical Psychologist employed in the Barnsley Community and 
Priority Services Trust. Dr Andrew Thompson and Dr Gerry Kent are Senior 
Clinical Psychologists, Clinical Lecturers and Research Supervisors on the 
Sheffield University Clinical Psychology training course. They work together on 
studies like this to increase knowledge about the psychological effect of skin 
conditions and improve ways of helping people cope with them. 
What if I have a complaint? 
If you have any cause to complain about any aspect of the way you have been 
approached or treated during the course of this study, in the first instance, please contact 
the Research Supervisors listed above. If this is not satisfactory, the normal National 
Health Service complaints mechanisms are open to you and are not compromised in any 
way because you have taken part in a research study. You can use the hospital 
complaints procedure through Dr Chris Welsh, Medical Director, on 0114 271 2178. 
You can also contact: 
The Sheffield Teaching Hospitals Patient Advice and Liaison Service, 
Janet Wainwright (Patient Representative) 0114271 245011900, 
Barnsley District Hospital Complaints Manager 
Julian Harris - 012267779841730 f)OO 
What happens next? 
If you decide you would like to take part in this study, please fill in the Research 
Consent Form. We will then give you a booklet of questionnaires. If you choose to 
complete it later, please return it in the prepaid envelope provided. 
Thank you for taking the time to read this form. 
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APPENDIX 12: RESEARCH CONSENT FORM 
RESEARCH CONSENT FORM 
TITLE OF PROJECT: A STUDY INTO HOW YOU FEEL ABOUT YOUR SKIN 
The patients should complete the whole of this sheet themselves. Please read the 
following questions and cross out Yes or No as necessary. 
Have you read the Research Information Sheet? Yes No 
Have you had an opportunity to ask questions and discuss this study? 
Yes No 
Have you received satisfactory answers to all your questions? 
Yes No 
Have you received enough information about this study? Yes No 
Who have you spoken to? Dr Mr. Ms . ............................................ . 
(Do you give your permissionfor us to access your notes? Yes No) 
Do you understand that you are free to withdraw from this study? 
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• at any time 
• without having to give any reasons for withdrawing 
• and without any affects on your future treatment 
• in extreme cases of distress, the researcher may inform your 
consultant 
Yes No 
Do you agree to take part in this study? Yes No 
Signed ....................................... Date ...................................... . 
Name (IN BLOCK LETTERS) ..................................................... . 
Signature of Witness ................................................................ .. 
Thank you for taking the time to complete this form. 
APPENDIX 13: SELF-REPORT FORM 
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IDNo. A STUDY INTO HOW YOU FEEL ABOUT YOUR SKIN 
This form gives you the chance to tell us how you feel about your skin. 
If your skin condition has a name, please write it here ........................... .. 
How long have you had your skin condition? 
Your sex .............................. Your age .......................................... .. 
Date ................................................................. , ......... 1 •• 2003 
These 3 short questions ask you to rate the extent of your skin 
condition on different parts of your body on a scale of 1 - 10, by 
ticking a number. 
Myface is: 
1 2 3 4 5 6 7 8 9 10 
Practically free of problems In a Bad State 
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My hands are: 
1 2 3 4 5 6 7 8 9 10 
Practically free of problems In a Bad State 
My body is: 
1 2 3 4 5 6 7 8 9 10 
Practically free of problems In a Bad State 
Thank you for taking the time to fill in this form. 
APPENDIX 14: CLINICIAN REPORT FORM 
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ID No:. A STUDY INTO HOW YOU FEEL ABOUT YOUR 
SKIN 
Clinician Report Form 
This form gives you the chance to rate the patient's skin condition. 
D· . lagnosls .................................................................................................. . 
Th~se 3 short questions ask you to rate the extent of the patient's skin 
condition on different parts of their body on a scale of 1 - 10, by 
ticking a number. 
The patient'sface is: 
1 2 3 4 5 6 7 8 9 10 
Practically free of problems In a Bad State 
The patient's hands are: 
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1 2 3 4 
Practically free of problems 
The patient's body is: 
123 4 
Practically free of problems 
5 
5 
6 7 8 
6 7 8 
Thank you for taking the time to fill in this form. 
9 10 
In a Bad State 
9 10 
In a Bad State 
APPENDIX 15: DESCRIPTIVE STATISTICS 
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Std. 
N range minimum maximum mean Error Std. dev. variance 
age 162 87.00 16.00 88.00 45.5494 1.48907 18.95272 359.208 
clinician-report 162 9.00 1.00 body 
10.00 4.7716 .2131 2.71246 7.357 
clinician-report 162 9.00 1.00 face 
10.00 3.1667 .2015 2.56409 6.575 
clinician-report 162 9.00 1.00 hands 10.00 
2.6481 .1730 2.20240 4.851 
clinician-report 162 27.00 3.00 
total 
30.00 10.5988 .4008 5.10080 26.018 
duration of 
69.00 1.00 70.00 14.2315 1.2112 15.41629 237.662 condition In years 162 
HADS anxiety 162 20.00 .00 20.00 7.1358 .3285 4.18145 17.485 
HADS depression 162 17.00 .00 17.00 4.3210 .2656 3.37998 11.424 
HADS total 162 37.00 .00 37.00 11.5309 .5508 7.01035 49.145 
ISS self-esteem 162 27.00 3.00 30.00 15.2469 .3977 5.06242 25.628 
ISS shame 162 105.00 .00 105.00 29.0679 1.5885 20.21810 408.772 
self-report body 162 9.00 1.00 10.00 5.2963 .2139 2.72301 7.415 
self-report face 162 10.00 .00 10.00 3.3086 .1943 2.47292 6.115 
self-report hands 162 9.00 1.00 10.00 3.2963 .2175 2.76825 7.663 
self-report total 162 27.00 3.00 30.00 12.0370 .3982 5.06834 25.688 
Initial SSS total 162 126.00 12.00 138.00 84.0000 1.7734 22.57163 509.478 
1- learnt to live 162 4.00 1.00 5.00 2.2593 .0945 1.20329 1.448 
11- ashamed 162 4.00 1.00 5.00 2.6420 .1049 1.33569 1.784 
12-avold 162 
socialiSing 4.00 1.00 
5.00 2.1728 .0945 1.20341 1.448 
13- hiding 162 4.00 1.00 5.00 2.9568 .1070 1.36208 1.855 
sss14-worry 162 4.00 1.00 5.00 3.1173 .1056 1.34389 1.806 
sss15-thlnklng 162 4.00 1.00 5.00 3.2346 .0925 1.17713 1.386 
sss16-proud 162 4.00 1.00 5.00 3.6543 .0948 1.20723 1.457 
sss17- avoid 162 4.00 1.00 5.00 2.2963 .0926 1.17895 1.390 discussing 
sss 18-peopJe 162 4.00 1.00 5.00 2.6728 .0951 1.20985 1.464 
accept 
Sss19-people 162 4.00 1.00 5.00 2.4877 .1011 1.28652 1.655 
accept 
sss20-avold 162 11.00 1.00 12.00 2.4506 .1132 1.44055 2.075 Intimate contact 
sss23-as attractive 162 4.00 1.00 5.00 3.6543 .0936 1.19169 1.420 
sss24- avoid 162 4.00 1.00 5.00 2.0741 .0925 1.17719 1.386 
touching 
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sss25-control 162 4.00 1.00 5.00 3.0617 .0942 1.19882 1.437 
sss26-despondent 162 4.00 1.00 5.00 2.9506 .1046 1.33189 1.774 
sss27-avold people 162 4.00 1.00 
touching 
5.00 2.6852 .1071 1.36264 1.857 
sss3-unattractlve 162 4.00 1.00 5.00 3.4568 .1014 1.29067 1.666 
sss30-one aspect 162 4.00 1.00 5.00 2.3457 .1034 1.31556 1.731 
sss4- avoid mirror 162 11.00 1.00 12.00 3.0123 .1162 1.47857 2.186 
sssS-rules life 162 4.00 1.00 5.00 2.6728 .1028 1.30850 1.712 
sss6-others stare 162 4.00 1.00 5.00 2.7531 .0975 1.24143 1.541 
sss 7 -different 162 4.00 1.00 5.00 2.7469 .0996 1.26742 1.606 
sss8-beautlful 162 4.00 1.00 5.00 3.8333 .0885 1.12703 1.270 
sss9-avold 162 4.00 1.00 5.00 1.7531 .0817 1.03996 1.082 
treatment 
Final SSS total 162 87.00 27.00 114.00 66.9444 1.3968 17.77892 316.090 
APPENDIX 16: SSS FINAL VERSION 
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SSS (final version) IDNo Date: 
Here is a list of statements describing feelings and experiences about your skin that you 
mayor may not have. Many people have had these feelings at some time while others 
will rarely or never have had these feelings. Please try to be as honest as you can in 
responding to each statement. 
Please read each statement carefully and circle the number on the right that best 
describes how often it has applied to you over the last week. 
Never rarely sometimes often always 
1. I've learnt to live with my skin condition 2 3 4 5 
2. I avoid looking at my skin the mirror 2 3 4 5 
3. My skin looks unattractive 2 3 4 5 
4. I avoid undressing in front of people 2 3 4 5 
5. My skin condition rules my life 2 3 4 5 
6. Others stare at my skin 2 3 4 5 
7. My skin makes me different 2 3 4 5 
8. My skin is beautiful 2 3 4 5 
9. I avoid getting treatment for my skin 2 3 4 5 
10. I am ashamed of my skin 2 3 4 5 
II. I avoid socialising because of my skin 2 3 4 5 
12. Hiding my skin makes me feel better 2 3 4 5 
13. I worry how my skin looks to others 2 3 4 5 
14. I find myself thinking about my skin 2 3 4 5 
15. I am proud of my skin 2 3 4 5 
16. I avoid discussing my skin 2 3 4 5 
17. I believe that people accept my skin 2 3 4 5 
18. I avoid intimate contact because of my 2 3 4 5 
19. My skin is as attractive as other people 2 3 4 5 
20. I avoid touching my skin 2 3 4 5 
21. I can control my skin condition 2 3 4 5 
22. I feel despondent about my skin 2 3 4 5 
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23. I feel good when people touch my skin 
24. My skin condition is only one aspect of me 
2 
2 
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3 
3 
4 
4 
5 
5 
APPENDIX 17: CORRELATIONS BETWEEN FINAL SSS ITEMS, HADS SUB 
AND TOTAL SCALES AND SSS 
Correlation (r) HADS HADS anxiety HADS total ISS 
item depression 
I-Learnt to live 0.31 ** 0.35** 0.37** 0.39** 
2-Avoid mirror 0.26** 0.16 0.21 ** 0.24** 
3-Unattractive 0.18* 0.33** 0.29** 0.30** 
4-Avoid 0.05 0.10 0.10 0.16* 
undressing 
5-Rules life 0.40** 0.48** 0.47** 0.43** 
6-0thers stare 0.13 0.22** 0.20* 0.22** 
7-Different 0.20* 0.26** 0.24** 0.34** 
8-Beautiful 0.36** 0.45** 0.45** 0.40** 
9-Avoid 0.04 0.00 0.01 0.10 
treatment 
ll-Ashamed 0.30** 0.36** 0.36** 0.44** 
12-Avoid 0.34** 0.35** 0.80** 0.46** 
socialising 
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13-hiding 0.17* 0.36** 0.29** 0.31 ** 
IS-Thinking 0.36** 0.52** 0.50** 0.49** 
16-Proud 0.29** 0.40** 0.38** 0.40** 
17-Avoid 0.18* 0.19* 0.22** 0.30** 
discussing 
18-people accept 0.16* 0.22** 0.21** 0.26** 
21-worrying 0.36** 0.31** 0.35** 0.40** 
23-as attractive 0.27** 0.34** 0.38** 0.25** 
24-1 avoid 0.21** 0.19* 0.22** 0.21 ** 
touching 
25-0thers avoid 0.37** 0.38** 0.40** 0.30** 
touching 
26-Despondent 0.33** 0.48** 0.468** 0.46** 
162 
27-1 avoid 
people touching 
30-0ne aspect 
*P<0.05 
**P<O.Ol 
0.31 ** 
0.13 
0.32** 0.35** 0.38** 
0.12 0.13 0.22** 
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CRITICAL APPRAISAL 
1 INTRODUCTION 
This section provides a critical appraisal of the present study, tracing it from its initial 
stages to its current stage of completion. The appraisal has four sections: (I) conception, 
(2) implementation (3) learning and development, including methodological limitations 
of the study, clinical implications, recommendations for further study and ethical issues 
(4) reflections on the research process, including on the current profile of psychology 
and the importance of supervisory relationships. 
2 CONCEPTION 
During my time as a trainee clinical psychologist, there was an increased 
acknowledgement of the psychological impact of skin conditions within the NHS (All 
Party Parliamentary Group on Skin, 2003) and other agencies. This emphasized the 
need for research mto the assessment of dermatological distress, in order that it is better 
understood, and effective interventions developed. It led, among other developments, to 
the formation of a psychodermatology group, comprising of psychologists, psychiatrists 
and dermatologists. This represented the first professional synthesis of psychology and 
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dermatology professionals and had its inaugural conference in May 2003 in London. In 
December 2003, the first conference of the Centre for Appearance Research was held in 
Bristol, to reflect the importance of appearance-related issues to theory, research and 
practice. The latter featured a keynote speech by a member of Changing Faces, who 
specialize in and support people around the psychosocial aspects of disfigurements, 
including those resulting from skin conditions. My academic supervisors were involved 
in both these events and had invited me along. 
Though the psychodermatological movement was generating a number of papers on 
interventions, it transpired that there was only limited understanding of the mediating 
factors between dermatological conditions and psychological distress. It was concerning 
that those factors predictive of skin distress were poorly understood and had received 
little examination in relation to clinical psychology. Moreover, it was difficult to see 
how interventions could be efficacious without a clearer understanding of the 
psychological mechanisms of skin distress. A measure was needed to assess why some 
people with skin conditions became distressed, while others seemed to adjust and cope 
well. 
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During introductory research sessions in the first year of the Sheffield course, I was 
increasingly aware of my previous experience of eczema and of its considerable 
personal impact of my self-perceptions and social life. This was salient because of the 
stress engendered by course demands and its ongoing effects on my skin and that of my 
peers. Although this personal experience was distinct from my awareness of skin 
research, I was aware that there was considerable expertise around both health 
psychology and disfigurement within the department and that a previous trainee, Dr 
Kellett, working locally as a senior clinical psychologist, had proposed a theory of 
dermatological shame. Shame had also been identified as a key emotion by both my 
academic supervisors. I became keen to conduct a third year research project that would 
seek to bridge both areas. More importantly, this approach offered a theory-informed 
strategy that could contribute to psychodermatological interventions. One of the key 
challenges of the whole research process was to concentrate on creating a tool that could 
bring clinical benefit to individuals in distress and to allow myself to be motivated by 
this. The next stage involved consulting with my clinical supervisor to decide upon a 
structure and way forward. 
3 IMPLEMENTATION 
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After discussions with Dr Kellett, we agreed on the necessity to examine further the 
theory of dermatological shame in order to better assess the psychological impact of 
skin distress. At the same time, meetings with local consultant dermatologists in 
Barnsley arranged by Dr Thompson confirmed their belief in the salience of 
psychological factors to skin diseases and their interest in the study. Their stance on the 
role of psychological factors in skin distress facilitated a strong yet flexible working 
relationship that I feel endorsed the role of clinical psychology in dermatology clinics. 
The initial research proposal was completed and provisional consent to conduct the 
study at Barnsley District General Hospital Dermatology department obtained. 
This study would use the theory of dermatological shame (Kellett, 2002) to construct a 
psychological instrument to assess skin distress. Dr Kellett and Dr Kent was keen to 
further explore this idea, in order to consolidate its conceptual status. 
3.1 Literature Review 
Keen to present a strong rationale for the present study, I explored a number of areas of 
related literature, including shame assessment, psychological factors in cosmetic 
surgery and cosmetic rehabilitation. However, there was little interface between the 
shame assessment literature and health psychology, insufficient psychology-driven 
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studies into surgery and cosmetic rehabilitation was overly medical. Therefore, it 
seemed logical to focus the present review on evaluating existing scales that had 
attempted to assess the impact of skin conditions on individuals' lives. 
Although I had some personal experience of living with a skin condition and an 
awareness of their psychological impact, I had to familiarize myself with the different 
perspectives from which skin distress had been assessed, for example, the theories of 
body image and stigma. It was often difficult to judge how far into each theory it was 
necessary to probe in order to make an infonned evaluation of each scale. I usually 
acquired this knowledge by consulting book chapters recommended by my supervisors. 
Moreover, it seemed to take a huge amount of effort and practice to understand the 
psychometric criteria by which I was to evaluate each scale, for example the subtle 
differences between construct and criterion validities. This often left me feeling 
deskilled and overly dependent on explanations from Dr Simpson, who provides 
statistical expertise to the department, which I imagined were both repetitive and 
monotonous for him. It did not help that textbooks on this subject often appeared to 
offer slightly different definitions. Reading through the original papers provided context 
in which to make sense of these concepts and I finally began to take an overview of 
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critical themes within the literature, learning as I went. Slowly, I began to accept that I 
did not need to comprehend everything fully in order to begin the research process, 
which allowed me to proceed with ethics procedures. 
3.2 Ethical and Clinical Approval 
My experience of obtaining ethical approval from the University of Sheffield Research 
Sub-Committee and Barnsley Research Ethics Committee was somewhat more 
parsimonious and constructive than I had anticipated. This was doubtless the result of 
thorough examination of the research proposal by my supervisors and numerous 
subsequent amendments on my part. 
The Research Sub-Committee suggested only that I abbreviated the questionnaire titles 
to minimize participants' potential negative affect about completing a shame scale. 
They endorsed the inclusion balance of shame-related and more positive items in the 
SSS. The Ethics Committee's concerns were also concerned largely on participants' 
well-being and safety, requiring a clearer protocol regarding clinically significant 
depression scores and suggesting that I check the scales further for readability. These 
concerns were addressed and seem likely to have facilitated implementation by 
improving the scales' face validity and increasing my confidence in dealing with any 
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risk issues. The granting of ethical approval, though crucial, did not feel like an 
achievement, as there was so much work yet to be completed. 
3.3 Implementing the Project 
My recollection of the project proper was dominated by positive experiences of the 
participants. Remaining with them while they completed the questionnaires allowed me 
first-hand experience of their stories and conferred a number of advantages: I was able 
to address their queries, monitor the face validity of items, collect qualitative comments 
on the scales and feed back to the consultants if any participants appeared particularly 
distressed. Though shame scales have been criticized for an over-reliance on negative 
items, participants did not appear to find items based on "skin pride" meaningful. 
Conversely, my presence may have lengthened the process of data collection and 
influenced participants' responses. 
On balance, however, I believe that face-to-face contact with dermatology staff and 
outpatients enriched this thesis because I of my learning about skin conditions and their 
associated distress from their experience and my own. Hearing about patients' 
experiences also underlined the need for a screening measure of skin distress. It was 
gratifying to learn that informing the consultants about those patients who met caseness 
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on the HADS was clinically useful. One of the consultants commented that although she 
was aware of many of them, the HADS had identified others whom she had not realized 
were significantly distressed and had been able to direct towards appropriate sources of 
support. Again, this was a timely reminder of the clinical meaningfulness of this 
research, which helped to motivate me when the process became turgid. A number of 
methodological issues relating to the more rigid process of scale development will now 
be explored below. 
4 LEARNING AND DEVELOPMENT 
It seems appropriate to begin this section with my considerable exposure to the SPSS 
computer package in the course of this study. I found my lack of basic statistical skill 
frustrating at times, but was encouraged by the creativity of the analytic process. I have 
begun to learn that meaningful statistical analysis requires synthesis between a science 
and an art, and there is often more than one appropriate way to investigate data. 
In terms of professional development, I would say that my preoccupation seemed to 
detract from clinical considerations at times. I didn't feel like reading outside this thesis 
and would occasionally be distracted, say in supervision, by a pressing research query. 
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Luckily, I benefited from the support of a supervisor who knew only too well the 
potential strain of these sometimes conflicting demands. Together, we developed a 
structured yet flexible approach to time management that allowed me to prioritize, plan 
and crucially, pace tasks on a week-to-week basis. This understanding was vital to my 
well-being as it reassured me that no area of my work was being undersold. 
It does not feel like sufficient time has yet elapsed since the hand-in date to evaluate 
fully the role of this thesis in my learning and development. It was often difficult to 
consider how it was contributing to my skills as a clinical psychologist and I suspect 
that this will only become clearer after some years spent as a qualified clinician. It came 
almost as a surprise when the dermatology consultants thanked me for my involvement 
in their department and requested that I presented my research to them and to a wider 
dermatology forum. On reflection, the pressure of the thesis time schedule means that it 
is easy to forget its clinical implications and potential application. This reminder served, 
therefore, as encouragement to ensure that the study was clinically useful to those who 
might read it. 
My personal learning and development from this thesis remain similarly hazy, perhaps 
as my sense of achievement is incomplete. Writing this appraisal reminds me of the 
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pleasures of writing creatively and from personal experience, which may, one day, 
encourage me back into writing about my work as a psychologist. I suspect, however, 
that that might be from a more experiential perspective than this study. Perhaps this 
process of reflection will be facilitated further by another five years of clinical work, in 
which the indulgence of research may start to become an attractive distraction. 
Certainly, undertaking this project has developed my determination to secure CPD time 
and support as a qualified clinical psychologist, and inspired me to seek a position in a 
department which is research aware and active. This was by no means, my only 
reflection on the research process. 
4.1 Methodological limitations 
From a methodological perspective, this study had a number of limitations that further 
research might improve upon. The key areas for improving the study involve the use of 
measures, participant characteristics and generalisability. Ethical issues are also alluded 
to in this section. 
4.1.1 Measurement issues 
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Using a clinical cut-off of 11 for HADS sub-scale scores was considered during data 
analysis to investigate the discriminative validity of the SSS between those participants 
meeting clinical "caseness" and those who did not. A score of eleven or above was used 
in its development as suggesting an increased probability of mood disorder, and is the 
recommended cut-off score (Love, Kissane, Bloch & Clarke, 2002) and has been shown 
to be a rigorous identification threshold (Love et al., 2002; Martin & Thompson, 2000; 
Picardi, Abeni, Renzi, Braga, Melchi et al., 2003), which increases the HADS' 
predictive value. However, using a cut-off point on a continuous variable such as this 
would have resulted in a loss of statistical power and increased the probability of type 1 
errors, by creating a false dichotomy between participants experiencing distress and 
those who were not. Therefore, HADS scores were treated as continuous variables for 
purposes of statistical testing. It is arguable that this method failed to provide a thorough 
examination of the SSS's external validity and that this could have been investigated 
using a median-split division in HADS scores. It is possible that the omission of a cut-
off failed to identify those participants with "borderline" anxiety and depression that 
might also have correlated with skin shame. However, though Richards, Fortune, 
Griffiths & Main (2001) argued that the HADS had low specificity in identifying 
clinically significant psychological morbidity, its generalisability in chronic illness, 
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brevity and wide utilization in clinical health settings seemed to make it the most 
appropriate instrument for this study. 
Conversely, the ISS appeared to lack face validity within the sample population, 
perhaps due to its dearth of skin specific items. Many participants found its tone rather 
"catastrophic", indicating, perhaps, that its usage is inappropriate outside mental health 
settings. Though it had been used in empirical research into shame, its lack of salience 
within dermatological populations may have meant that it failed to identify the 
constellation of emotions experienced by this group. Using a scale more meaningful to 
participants may have produced different effects, but the ISS was useful in determining 
the external validity of the SSS. 
The SSS might be criticized on the grounds that it has few treatment-related items, such 
as compliance, that have been shown to contribute to psychodermatological distress 
(Fortune, Main, O'Sullivan & Griffiths, 1997). The perceptual disease severity indices 
used in this study may have been improved by employing a 100mm visual analogue 
scale to improve accuracy (Rapp, Cottrell & Leary, 2001). As all data was self-reported, 
the extraneous effects of common method variance contaminate the results of this study 
potentially, although clinical information was triangulated to some extent by the 
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inclusion of the clinician report measure. However, this methodology may have been 
advanced by the inclusion, perhaps, of disease and distress ratings from a significant 
other with knowledge of the participant's experience of living with a skin condition. 
Behavioural ratings might also have helped clarify the relationship between affective 
and behavioural avoidance. 
4.1.2 Participant Characteristics 
A number of factors regarding the study sample appear to affect the potential 
generalisability of results. As data was not collated regarding the number of patients 
asked to participate in this study and the proportion who refused, it cannot be assumed 
that this study is entirely representative of all dermatological outpatients. It may be that 
those patients experiencing the most skin distress were most likely to attend a 
dermatology outpatients' clinic and thus artificially increased the prevalence of skin 
distress in this sample. Conversely, non-respondence may have been indicative of high 
levels of distress. As it was not possible to collect detailed data for non-respondents, 
and there was no control group, it is unclear whether or not participants' levels of 
distress were representative of the dermatological population and how they compare 
with other popUlations. It would have been useful to compare data from this sample 
with patients from another chronic disease group, as Fortune, Richards, Kirby, Bowcock 
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& Main et al. (2002a) used a sample of patients with chronic fatigue, although the skin-
specificity of the items may have rendered the SSS meaningless in non-dermatological 
contexts. 
As participants were recruited over a relatively short period and were not self-selected, 
the potential for selection bias was minimized and narrow confidence intervals utilized. 
The wide diversity of participants' chronic dermatological conditions enhances the 
SSS's external validity, although it should be noted that the sample included few 
patients with vitiligo, a condition which has undergone research into skin 
disfigurements (Papadopoulos, Bor, Legg & Hawk, 1998; Papadopoulos, Bor & Legg, 
1999a; Thompson, Kent & Smith, 2002), and shown markedly different results. 
Recruiting participants from other dermatology departments may have enhanced the 
ecological validity of this study and the generalisability of the results. The sample was 
culturally homogeneous and it would have been interesting to explore skin distress for 
people from cultures in which skin is more covered, for example. Investigating whether 
skin-related stigma and avoidance behaviours are reflected in societies in which skin is 
more concealed might inform the mechanisms of skin distress. 
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4.1.3 Ethical Considerations 
A number of ethical considerations regarding this study merit consideration. Self-
assessment of skin conditions may have proved to be a distressing procedure to some 
participants. However, most items appeared to be meaningful to participants, replicating 
the findings of Carr, Harris & James (2000), who reported that none of their participants 
from a clinical population was distressed at the content of problem-oriented items. 
Participants may have reassured by the introductory section of the SSS that stressed that 
some items would be relevant to some respondents, but not others, re-iterating that 
shame is not inevitable consequence of skin conditions. Participants were safeguarded 
by informing them of the NHS complaints procedures and providing them with the 
opportunity to access further psychological support via their consultant. Offering them 
the option of completing the questionnaires at home gave patients an opportunity to opt 
out of the study at a second stage. Clear language helped make this research accessible 
for those participants who did not have English as their first language or read well and a 
number were able to complete the questionnaires with help. However, though not ideal 
in terms of diversity, it was not be possible to include participants for whom English 
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was not their first language because of the complexities of translating standardized 
questionnaires. 
4.2 Clinical implications 
As reliability and validity testing of the SSS remains in its early stages, clinicians might 
view it with some caution, though its clinical meaningfulness to dermatological patients 
might be posited on the basis of this study. The brevity of the final 24-item SSS is 
comparable with existing psychodermatological measures, such as Skindex-29 (Chren, 
Lasek & Quinn, 1996) and may make it useful as a screening tool in primary and 
secondary, helping those who are most likely to benefit from psychodermatological 
treatment receive appropriate support. The SSS may allow clinicians to gather a relative 
breadth of information concerning psychodermatological distress within the least 
amount of clinical time, thus addressing the so-called "bandwidth-fidelity dilemna" 
(Cronbach & GIeser, 1965). Cronbach (1970) proposed, "When several questions are of 
about equal importance, it is more profitable to use a brief test giving a rough answer to 
each one, than to use a precise test answering only one or two questions" (p. 151). The 
SSS offers a multidimensional assessment of dermatological shame, including affective 
and behavioural domains and aspects of stigma and pride, which is central in 
understanding the experiences of those people with dermatological distress. Multi-
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dimensionality also increases the content validity in the SSS by ensuring more aspects 
of living with a skin condition are included. Used in conjunction with clinical 
interviews, it may help provide an index of the degree and nature of presenting skin-
related distress. It was decided not to determine a cut-off for clinical caseness on the 
SSS, but rather, to rely on clinical judgment and the information offered by individual 
items. 
Though a body of literature .exists around psychosomatic factors in chronic skin disease, 
especially in terms of aetiology (Panconesi, 2000), less has been written about the 
somatopsychic effects of skin conditions on the self and the emotional and social 
consequences of this. In short, there has been a bias in the directionality of 
. psycho dermatological writing to which this study may contribute. A body of research 
has suggested that people who are chronically anxious or depressed are more vulnerable 
to psychosomatic disease (Panconesi, 2000); whereas this study suggests that those with 
chronic disease may be more vulnerable to psychological disturbance. Subsequently, the 
findings of this study may help inform current cognitive-behavioural interventions, 
because they clarify to an extent which factors are most salient to individuals with skin 
disease, i.e. behavioural avoidance. As a protective factor of skin pride exists' for some 
people, clinicians might work towards enhancing this. Research into cognitive-
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behavioural management programmes as adjuncts in psoriasis therapy (Fortune et al., 
2002a; Richards, Fortune, Main & Griffiths, 2003) has demonstrated reductions in 
psoriasis severity, depression and psoriasis-related stress. Group-work around issues 
such as anticipatory anxiety and social avoidance have also reduced symptoms and 
improved patients' moods, through exposure to the group in vivo, thus reducing the fear 
of stigmatisation. This study underlines the need to tackle stigma and behavioural 
avoidance in order to enhance clients' ability to cope, and deal with social situations. It 
also reinforces the need to tackle chronic anxiety in many of this client group, in order 
to manage their condition and perhaps reduce symptoms in the process. 
4.3 Further research 
In the context of the study findings, the further conceptual development of skin-related 
distress is necessary to pinpoint the unique experience of some individuals with chronic 
skin conditions. Further studies of the SSS with a clinical sample of participants from a 
different chronic health group condition and non-clinical sample would generate 
comparative and normative data, while test-retest reliability analyses would demonstrate 
whether or not the SSS is measuring a stable or transient experience of dermatological 
shame. It would also be useful to assess the sensitivity of the SSS to skin improvement 
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after intervention, via a longitudinal study. Further theoretically-driven research, 
including confirmatory factor analytic investigation of the 4 factors, would build on the 
model of dermatological shame and help establish the SSS as an appropriate and 
validated domain-specific instrument. Further testing and refinement of the SSS via 
confirmatory factor analysis might achieve this. Longitudinal studies might also 
investigate whether dermatology populations are likely to have high pre-morbid levels 
of shame-proneness or anxiety, in order to differentiate dermatological shame from 
characterlogical factors and to deliver the most appropriate interventions. This may also 
inform whether people whose skin aetiology includes psychological factors are more 
likely to experience psychological problems. The application of further qualitative 
research based on dermatological shame to people with skin conditions might be 
valuable in generating a more complete theory of skin distress. Like quantitative skin 
research, existing studies have been conducted largely without a theoretical grounding, 
or limited to a single diagnosis and the application of a rigorous methodology such as 
IP A or grounded theory might facilitate a better understanding of the personal 
experience of skin distress across conditions. This would help increase the involvement 
of patients at every stage of the research process, not only to enhance face validity, but 
also to increase user-involvement in line with current NICE directives. 
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5 PROCESS REFLECTIONS 
My overwhelming feeling about writing the thesis was of my difficulty discarding 
material that I had created and invested in emotionally. This process, though 
challenging, was facilitated by receiving joint feedback from my supervisors wherever 
possible, which minimized the time-consuming task of editing work according to an 
individual's personal style, then re-editing in response to another. 
5.1 The profile of psychology and rise of the questionnaire 
What did strike me about this research process was the familiarity with which most 
participants engaged in the questionnaire process, many commenting that they had 
participated in studies with similar formats before. Many participants volunteered their 
ideas that the study was "about body image", or "how your mind affects your skin", 
which seemed to illustrate the increasing usage of psychological parlance in clinical, 
and perhaps, non-clinical populations. Whilst this usually appeared to enhance their 
engagement with the study, it should be noted that the participants' individual 
perceptions of what psychology is might also have primed them to generate a particular 
response set. It seems, however, to reflect the increasing awareness of psychological 
issues in healthcare settings and its salience within society in general, especially 
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perhaps, in the media. The expanding profile of psychology may have functioned as a 
means of normalizing contact with psychological services, so that it is less stigmatising, 
and patients are more willing to engage with it. 
The proliferation of psychology notwithstanding, I was struck by the speed with which 
many participants engaged in describing their feelings about their skin. While this was 
occasionally difficult to manage within the framework of this quantitative study, it 
suggested that the need for dermatology patients, and likewise those with other chronic 
illnesses, to receive holistic psychodermatological healthcare, as recommended. 
5.2 Supervision 
I feel incredibly blessed in terms of the research support I received throughout this 
project. Largely because my supervisors appeared to know what I needed as well as, and 
at times better, than I did. Their support ran the gamut of hypothesizing around tricky 
theoretical concepts to providing the containment and pastoral support that I needed. 
The faith of Dr Kellett and Dr Thompson in my abilities to both research and write 
allowed me to work independently but with the knowledge that no query was too naIve. 
Their ability to move up an intellectual gear stunned me on occasions but proved 
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invaluable and I felt reassured of their investment in the project. Being treated as a 
competent adult and colleague, as much as a trainee and amateur researcher, also 
allowed me to seek the type and level of feedback that I needed and to arrange deadlines 
with mutual respect. This illustrated the confidence factor, which I needed to conquer in 
order to produce the best thesis I could. 
In short, this process was less aversive than I had feared, in part because it helped 
address my research-related fears. In spite of my fears of research burnout, I still feel 
interested in psychodermatology and keen to develop a dermatology-related position, 
which feels like an achievement. It is my hope that this study can playa part in 
contributing to the development of interventions that can challenge perceptions and 
alleviate skin distress and it is repeating this mantra (as a form of self-talk) that has kept 
. me going. I don't perceive myself as a future research ace, but I never did before. I just 
hope that this project has been good enough and look forward to practicing clinically, as 
was my aim all along. Getting my life back seems like a pretty good outcome in the 
meantime. 
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